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You beat cancer by how you live, why you live, and in the manner in which you live 
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Hepatocellular carcinoma (HCC), which represents more than 80% of all liver cancer 
cases, is posing a serious threat to the human health, especially in South East Asia. It is 
estimated that in Vietnam, this disease is increasing dramatically with about 22,000 people 
affected per year and 95% of them will die. Liver cancer is rarely detected in early stage and 
once detected, treatment faces a poor prognosis in most cases. The therapeutic approaches 
against HCC depend on its stage of development, and include surgery, chemotherapy and 
radiotherapy. Chemotherapy involves the administration of compounds that act on cancerous 
cells by either killing them or preventing their proliferation. Currently, more than half of 
cancer chemotherapeutic small molecules used are derived from or inspired by natural 
products. 
Today, the very poor prognosis and a lack of effective treatments fully justifies the search 
of new molecules and therapeutic strategies against HCC. 
Vietnam is a country with favorable natural conditions for a rich and varied biodiversity. 
It is estimated that there are about 12,000 species of plants and nearly 11,000 marine 
organisms had been recorded so far until now. Despite this high potential source of original 
bioactive substances, only a very limited number of studies have been done to explore the 
Vietnam plants and marine resources for their cytotoxic properties and to isolate and 
characterize the active molecule. 
The present work was conducted on natural products originated from Vietnamese plants 
with the aim to identify natural compounds with potential anti-hepatocarcinoma activities. 
Two experimental screening approaches were used :  
 The first approach refers to a pharmacological screening method including the 
establishment of Vietnamese database of natural products. This database contains 
compounds isolated (and their structure determined) from medicinal plants that are 
commonly used in traditional prescriptions for liver protection. This approach 
allowed the identification of a family of ent-kaurane diterpenoids isolated from 
Croton kongensis Gagnep., which exhibit original cytotoxic, apoptotic and 
sensitization properties on human liver cancer HepG2 and Hep3b cell lines. 
 The second approach aimed at developing a “Virtual screening” strategy. Research 
was carried out on a database which is the collection of all known compounds 
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isolated or originated from Vietnamese plants using computational tool called 
Autodock. The objective focused on finding natural molecules that could abrogate 
the interaction between p53 and Mortalin, an hsp70 chaperone protein also 
identified as a marker for hepatocarcinoma, expecting that inhibition of mortalin – 
p53 interaction should result in the activation of the apoptotic process. In silico 
screening of a database of 354 natural compounds allowed the identification of 
solasonine as a potent inhibitor of p53 – mortalin interactions. Pharmacological 
studies confirmed that solasonine was able to inhibit mortalin - p53 interaction. 
This inhibition abrogated cytoplasmic sequestration of p53, allowing its 
translocation to the nucleus and inducing cell death of human hepatocellular 
carcinoma cell lines through p53-dependent pathways. 
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1. Cancer and Hepatocellular Carcinoma 
1.1. Cancer  
1.1.1. Overview of cancer 
Cancer is a term used for diseases in which abnormal cells divide without control and are 
able to invade other tissues. Cancer cells can spread to other parts of the body through the 
blood and lymph systems. There are more than 100 different types of cancers, most of them 
are named depending on which tissue or organ they come from, for example: cancer begins in 
the cells of the large bowel is called colon cancer (Hattersley L., 2013). Cancer types can be 
grouped into four main categories including: 
- Carcinoma: cancer that begins in the skin or in tissue that line or cover internal organs. 
There are a number of sub-types of carcinoma, including adenocarcinoma, carcinoma, 
squamous and transitional cell carcinoma. 
- Sarcoma: cancer that begin in bone, cartilage, fat, muscle, blood vessels or other 
connective or supportive tissue. 
- Leukaemia: cancer that starts in blood-forming tissue such as the bone marrow and 
causes large numbers of abnormal blood cells to be produced and enter the blood. 
- Lymphoma and myeloma: cancer that begins in the cells of the immune system. 
- Central nervous system cancers: cancer that begin in the tissues of the brain and spinal 
cord. 
Nowadays, cancer has become a major public health and it is attracting attention from all 
over the world. It could be caused in one of three ways, namely: incorrect diet, genetic 
predisposition and via the environment. It is estimated that approximately 95 % of all cancers 
are caused by life style and may take about 20 to 30 years to develop. 
Modern human is confronting with increasing incidence of cancer and cancer deaths 
annually (Reddy L., 2003). According to the most recent global burden of cancer study 
(GLOBOCAN) data from the International Agency for Research on Cancer 
(http://www.globocan.iarc.fr - GLOBOCAN, 2012), there were about 8,2 million deaths and 
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more than 14 million people affected directly by different types of cancer on world scale, the 
three most common being lung, breast and colorectal cancers (Figures 01 and 02). 
 
 
Figure 01 : Cancer incidence statistics worldwide in 2012 (GLOBOCAN 2012) 
 
 
Figure 02 : Most common cancer worldwide in 2012 (GLOBOCAN 2012) 
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In Vietnam, Ministry of Health has predicted that the 21st century will be the century of 
cancer, cardiovascular and other noncommunicable diseases due to the process of 
urbanization, industrialization, plus the sequela of war still exist and threaten human health 
every day (http://moh.gov.vn/pages/index.aspx; Anh P. T. H., 2002). According to the 
statistics in several oncology hospitals in Hanoi, Ho Chi Minh and some other provinces in 
2008, there are approximately 100,000 to 150,000 people suffer different types of cancer and 
over 73% of them (about 70,000 patients) die annually which makes Vietnam become one of 
the countries has highest mortal rate in the world and this number tends to increase in the near 
future. It is predicted by 2020, there will be about 200,000 new cancer cases and 100,000 
deaths per year in Vietnam (Vietnam National Cancer Hospital - http://benhvienk.vn).  
Despite the significant progress made in recent decades in researching treatments for some 
types of cancer, cancer prevention and cure remain elusive in many countries. The burden of 
cancer keeps increasing both in economically developed and developing countries as a result 
of population aging and growth as well as increasingly an adoption of cancer-associated 
lifestyle choices including smoking, physical inactivity, and “westernized” diets (Jermal A., 
2011).  
 
1.1.2. Aetiologies of Cancer 
The risk factors vary widely depending on different lifestyle, economic, social, climate or 
environment pollution. It is estimated that tobacco and smoking is the world leading cause 
followed up by unhealthy diet and obesity (World Cancer Report 2014). 
Until now, it is impossible for human to explain why one person develops cancer while 
another does not. However, many researches have pointed out that some risk factors may 
increase the rate of cell mutations that favor a person’s chance to develop cancer. They 
include intrinsic factors such as: age, gender or family history but many causes for this 
disease come also from external effects. These different factors are shown in Figure 03 and 
briefly presented below : 
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a. Modifiable risk factors 
 Tobacco and smoking: tobacco use is identified worldwide as the first leading 
cause of many cancers such as lung, oral cavity, esophagus or pancreas. 
  Unhealthy diet: diet is believed to be implicated in about 30% to 40% of all 
cancers. A diet high in saturated fats, lack of fibre, fruits and vegetables could 
increase the rate of getting breast, esophagus and prostate cancer. 
 Ultraviolet radiation (UV): sunlight is the main source of UV rays, being exposed 
to the UV is the major risk factor to several types of skin cancer.  
 Infectious agents: since the start of 20th century, infections are known to play a 
role in cancer. Worldwide, they are accounted for 15% to 20% of different types of 
cancer and especially high in developing countries. Basically, there are three types 
of infectious agents including: viruses, bacteria and parasites, for example: human 
papilloma virus, hepatitis B, C viruses.  
 Physical inactivity: an unhealthy lifestyle would increase the risk of some cancers 
such as: breast, colon, esophagus cancer. This factor is closely linked to the 
unhealthy diet with low nutrition. 
 
 
Figure 03 : Main factors causing cancer worldwide (Food, Nutrition, Physical activity, 
and the prevention of cancer: A global perspective., 2007)  
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b. Other modifiable factors 
 Alcohol: consuming too much alcohol would raise the risk of suffering some 
cancers such as: oral cavity, mouth, liver and esophagus. It should be noticed that 
drinking and smoking together even make the situation worse. 
 Socio-economic status (SES): SES is closely linked to the risk of developing 
certain cancers based on a person’s income, education level and occupation. For 
example: low SES is associated with lung, stomach and cervital cancer while high 
SES is responsible for breast and testicular cancer. 
 Occupational exposure: it has been estimated that around 3% to 6% of all cancers 
worldwide are caused by exposure to carcinogens in the workplace (Driscoll T., 
2005; Rushton L., 2012). Some common types of cancer factor a person can suffer 
include arsenic, asbestos, silica and benzenes.  
 Environmental pollution: this has become a serious issue in many developing 
countries with the pollution of air, water and soil which represents one of the 
factors causing about 4% of all cancers. 
 Food contaminant and obesity: it should be noticed that an unhealthy lifestyle 
leads to obesity and consumption of certain food contaminants such as aflatoxin, 
pesticides could pose a carcinogenic risk to human. The common cancers resulting 
from this field are liver, kidney, breast cancer. 
 Ionizing radiation: in daily life, we are all exposed to small amounts of naturally or 
manufactured radiation, for example the exposure comes from medical X-rays or 
in some war zones. This issue is also one among factors causing cancers. 
 
c. Non-modifiable factors 
 Age: as cancer takes time to develop, most of the cases are diagnosed in people 
older than 65 years old. This high rate could be explained by the combination of 
long time exposure to carcinogens and weakening of the body’s immune system. 
However, some cancers such as retinoblastoma, Wilm tumor occur almost 
exclusively in children because of gene mutations.  
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 Ethnicity – race: different genetic background between races or ethnicities would 
be an issue contributing to the risk of suffering cancers, especially in breast cancer. 
However, in most of the cases, the reason comes from different lifestyle and 
exposure to carcinogen agents. 
 Heredity: a small but significant proportion of cancers are due to inherited 
conditions. In some families, due to specific gene fault, they could have higher risk 
of developing certain cancers for example breast, ovarian or bowel cancer. 
 Gender: some cancers occur only in one gender due to different anatomy such as 
prostate in men and uterus in women. Some others occur in both genders but at 
different rates, for example oral cavity, liver. 
 
d. Other risk factors 
 Hormonal and reproductive factors: sex steroid hormones such as estrogens could 
affect the development of some cancers in women like breast and ovary cancer. In 
men, testosterone hormone is involved in prostate cancer. However, these factors 
only contribute a small account to the burden of these cases. 
 Immunosuppression: the immune system plays an important role in defending the 
body against cancer. Certain medical drugs and infections are the most common 
factors as immunosuppressants. The best known factor for this case is HIV which 
is associated with Kaposi’s sarcoma (Sloan F. A. and Gelband H., 2007). 
 Medicinal drugs: in some cases, hormonal drugs can cause cancers while others 
reduce the risk. It has been reported that certain anti-cancer agents are carcinogen 
to human which cause another cancer years later (Harris C. C., 1976). 
 
1.1.3. Mechanisms of cancer development 
Cancer is, in some aspects, a genetic disease since many cancer types arise from the 
alteration (mutation) in the deoxyribonucleic acid (DNA) of normal cells.  Cancer begins with 
damage to one or more genes in a single cell. This damage causes cells to proliferate 
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uncontrollably and to be transformed in abnormal cells. At this stage, if the body’s immune 
system does not recognize and kill these abnormal cells, then they will develop to even more 
abnormal and finally converted to cancer cells. The characteristics of cancer cells is they 
divide more rapidly than normal cells and start to pile on top of each other and form 
malignant tumor, these tumors will invade healthy tissues. The process of a normal cell to 
become a cancerous tumor usually take years to develop (Figure 04). 
 
 
Figure 04 : Development process of cancerous cells. How a tumor develops: Damage to 
genes in a single cell (mutations) can lead to progressively more abnormal cells. Eventually, 
abnormal cells may become cancerous cells, which often divide quickly and do not die.  (The 
Metastasis Research Society UK, http://www.metastasis.icr.ac.uk) 
 
Several hallmarks of malignant cancer are autonomous growth; invasion and metastasis. 
Histologically, cancer is characterized by some morphological alterations, including changes 
in tissue architecture, cytological abnormalities of both the nucleus and cytoplasm and the 
presence of abnormal mitosis. 
In medical field, the term “stage” is used to describes the severity of a person’s cancer. As 
shown in Figure 05, during early stages, there may be only small cancerous tumor, if they 
remain localized, then the disease is curable by surgical removal if the tumor is detected in 
time. However, malignant tumors tend to metastasis. In more advanced stages, the tumors 
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growth larger and start to break away from parent mass, enter the lymphatic or vascular 
circulation and move to different sites in the body. This process makes surgical removal of 
metastasis difficult if not impossible and it is no longer possible to cure the disease. 
 
 
Figure 05 : Metastasis mechanism of cancerous cells. How a tumor spreads: Metastases 
happen when cancer cells from the original tumor spread to different parts of the body, and 
eventually form secondary tumors at sites distant from the original tumor. (The Metastasis 
Research Society UK, http://www.metastasis.icr.ac.uk) 
 
1.2. Hepatocellular Carcinoma (HCC) 
1.2.1. Overview of Hepatocellular Carcinoma 
Liver cancer comprises diverse, histologically distinct primary hepatic neoplasms, which 
include hepatocellular carcinoma, intrahepatic bile duct carcinoma (cholangiocarcinoma), 
hepatoblastoma, bile duct cystadenocarcinoma, haemangiosarcoma and epitheliod 
haemangioendothelioma (Anthony P. P., 2002). Among these, HCC – arises from hepatocytes 
or hepatocyte progenitors, which are the parenchymal cells of the liver (American Cancer 
Society, Facts and Figures, 2010) – representing more than 80 % of all cases. Due to the high 
tolerance of liver, HCC is rarely detected in early stage and once detected, treatment faces a 
poor prognosis in most cases (Singh R., 2009). 
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Nowadays, HCC has become the sixth most common cancer and the second leading cause 
of death from cancer worldwide with estimated 746,000 deaths and 782,000 new cases in 
2012 (GLOBOCAN, 2012). More than 80% of these deaths and new cases occur in the less 
developed regions, in some parts of Asia and Africa, especially in Eastern Asia, the ratio is 
more than 100/100,000 population, whereas in Eupore and North America, it is estimated as 
2-4/100,000 population (Bain I., 1997; Duvoux C., 1998) (Figure 06).  
 
 
Figure 06 : Worldwide Incidence of Hepatocellular Carcinoma (International agency for 
research on cancer 2013) 
 
In Vietnam, liver cancer is on the rising trend. It is estimated to have 22,000 liver cancer 
cases per year, of which 21,000 die, or 95.4% of the total cases - the Hanoi Moi newspaper 
reported from a seminar jointly held by Bach Mai Hospital and Military 108 Hospital. 
According to Vice Chairman of Bach Mai Hospital - Mai Trong Khoa, liver cancer has a high 
disease incidence rate in Vietnam and over the world with 780,000 new cases globally every 
year and 750,000 of which die. In terms of incidence and mortality, liver cancer ranks second 
and first in men and third and second in women in 2012 (GLOBOCAN 2012). 
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In addition, gender can also influence the risk of infection with a clear predominance in 
males at worldwide scale, ranging from 8:1 in countries with high frequency of HCC to about 
2:1 in nations with low frequency. For all the above reasons, it is important to recognize that 
liver cancer is becoming a major public health problem all over the world. 
 
1.2.2. Aetiologies of Hepatocelluler Carcinoma 
There are many factors that have been considered to be reasons for hepatocarcinogenesis 
including chronic alcohol abuse, consumption of contaminated food (Aflatoxin B1), chronic 
Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infections, fatty liver diseases 
associated with obesity, non-alcoholic fatty liver disorders (NAFLD), diabetes, fungal toxins 
(aflatoxins), toxic industrial chemicals, environment pollutants and some certain metabolic 
disorders (Badvie S., 2000; Paraskevi A. F., 2006).  
 
 
Figure 07 : Hepatocellular carcinoma development process (Levrero M., 2006) 
 
The most prevalent causes of HCC are variable due to regionality, for example HBV and 
HCV infections are the major risk factors worldwide, whereas these cases constitute less than 
half in the USA. In most western countries, the major risk factors of hepatocarrcinogenesis 
are alcoholic cirrhosis and obesity-related non-alcoholic fatty liver diseases (American Cancer 
Society, 2010). In Vietnam, HBV infection is the major cause of chronic liver diseases, 
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including HCC, which increase constantly and are estimated to burden by 2025 (Nguyen 
V.T., 2008). 
 
1.2.3. Pathogenesis of HCC development 
Mechanisms leading to the development of HCC are abundant according to the variability 
of HCC aetiologies, which results in a high genetic and phenotypic heterogeneity of these 
tumors. HCC develops in a multi-step process in chronically injured livers. Liver injury might 
result from one or more of the major HCC risk factors, such as HBV/HCV infections, 
alcohol-related cirrhosis, Aflatoxin B1 or genetic disorders. A survey of the diverse 
hepatocarcinogenesis mechanisms points to common pathogenetic pathways and processes 
(Figure 08) (Paraskevi A. F., 2006). 
 
 
Figure 08 : The suspected mechanisms of hepatocarcinogenesis for various risk factors 
(Paraskevi A. F., 2006) 
 
The initial liver injury signified itself as necrosis then followed by continuous cycles of 
proliferation and damage. On the other hand, these continuous cycles of proliferation and 
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necrosis cause telomere shortening, liver injury provokes activation of stellate cells, which 
play a role in the synthesis and deposition of collagen. Both of these contribute to the 
formation of abnormal liver nodules, together with fibrous scar tissue, a state which is called 
cirrhosis (Paraskevi A. F., 2006; Feo F., 2009). Formation of hyperplastic nodules is the next 
step in the pathogenesis of HCC, which are still considered as pre-malignant lesions. Together 
with the accumulation of genetic damage, leading to moderate genomic instability, these pre-
malignant lesions progress into dysplastic nodules which have the ability of autonomous 
growth. Dysplastic nodules are composed of cells with altered characteristics such as 
increased nuclear to cytoplasmic ratio and they tend to form mild trabecular disarrays (Feo F., 
2009). 
Figure 09 summarizes the current knowledge of the genetic and genomic events 
associated with the development of HCC. The HCC neoplastic evolution proceeds through a 
multi-step histological process that is less well defined than that of other cancer types 
(Paraskevi A. F., 2006). 
 
 
Figure 09 : Histopathological progression and molecular features of HCC (Paraskevi A. 
F., 2006) 
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1.3. Treatment against cancer 
Currently, many therapies are available. The type of treatment that patients received will 
depend both on their type of cancer and the advantages/disadvantages of each method. In 
general, doctors usually use the combination of several methods in order to obtain the best 
therapeutic effect for curing cancer. Some main types of cancer treatment are described 
below: 
a. Surgery: surgery is one of the most effective method for cancer treatment. Surgery 
includes two main options: the first is open surgery in which the surgeons make large 
cut to remove tumors out of patient’s body, the second is minimal invasive surgery 
with small cut and use of laparoscope with special tools to insert inside the body and 
operate the surgery. 
b. Chemotherapy: chemotherapy treatment uses drugs to kill cancer cells, the number and 
type of drug used depending on the patient’s cancer and their metastasis. 
Chemotherapy is utilized either to cure cancer when the tumor is localized and does 
not spread or to ease the cancer symptoms by limiting tumor growth and spreading 
when cancer has reached the later stage. 
c. Targeted therapy: this method focuses on the difference between normal and 
cancerous cells in order to minimize adverse impacts on healthy tissues. There are two 
main forms of targeted drugs including small-molecule drugs that penetrate cells 
easily and attack them from inside. The second type is monoclonal antibodies which 
are the man-made versions of large immune system proteins acting at the outer surface 
of cancerous cells. 
d. Radiation therapy: radiotherapy uses high energy particles or waves to damage 
cancerous cells. Patients usually receive high doses of radiation to slow cancer cell 
growth and to ease problems caused by tumors such as breathing trouble or bladder 
control. Currently radiation is considered to be one of the most common method, 
however, the side effect is that normal cells can also be harmed during treatment.  
e. Immunotherapy: in medicine, doctors also use the immune system to fight against 
cancer. This is a method that either stimulates or eduquates the patient’s immune 
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system to kill cancerous cells. Some common types of immunotherapy can be named 
like monoclonal antibodies, vaccines, cytokines, Bacillus Calmette-Guérin (BCG). 
f. Photodynamic therapy: this method uses photosensitizing agents in combination with 
certain kinds of light to kill cancer cells. The mechanism of this technic consists in 
injecting the agents either into the bloodstream through a vein or on the skin, after a 
certain amount of time, cancer cells will absorb the drugs then light will be applied. 
Under the effect of light, the drugs will form some types of chemical that kill the cells.  
g. Hormone therapy: this method can be applied for some hormone-dependent cancers 
such as prostate, breast or ovarian cancers. This therapy can be successful to slow or 
stop tumors from growing by either stoping the production of certain types of 
hormone or preventing hormones to interact with their receptors. 
h. Laser treatment: the advantage of this method is laying on the thin and focus beam of 
laser’s light, which should therefore not harm normal cells nearby. There are three 
main types of laser commonly used in treatment including carbon dioxide, argon and 
neodymium. Doctors usually use laser to destroy the small areas of cancerous cells or 
to shrink tumors in order to make them easier to remove in surgery. Due to the 
functions above, laser treatment is a very effective method in support to other cancer 
treatment therapies. 
i. Stem cell transplant: this method is used in the treatment of some types of cancer such 
as leukaemia, lymphoma and myeloma. When a patient takes a high dose of 
chemotherapy or radiation, not only cancerous cells are killed but also stem cells in the 
bone marrow.  Thus, patients need to receive additional stem cells to survive. 
Normally, stem cells are collected from patient’s blood or from other donor then they 
are transferred through a drip to replace the dead one.  
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Figure 10 : Estimated percentage of patients able to access radiotherapy in 2013 (The 
Cancer Atlas, second edition) 
 
Figure 10 presents an example of the differences in medical quality for cancer treatment 
between developed and developing countries base on the number of patients receiving 
radiotherapy in which the number of medical centers in developing countries being overload 
seriously. In conclusion, bases on the rapid development of medical technologies, there may 
be a hope for human to cure cancer in the near future, however, it should be noticed that it is 
always better to keep a healthy lifestyle than suffering diseases, as a quote said: “An ounce of 
prevention is worth more than a million pounds of cure” (David Agus). 
Today, the various chemotherapeutic approaches are mostly described in the frame of 
clinical trials. In systemic treatment, sorafenib is the only molecule showing some efficacy for 
unresectable and advanced metastatic HCC, whereas gemcitabine, doxorubicine and 
capecitabin display only marginal activites. 
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2. Natural products as sources of anticancer agents 
2.1. The origin of medicine 
Among all the medicines being provided on the international market, more than 60% of 
them are derived from or inspired by natural products and only 35% are totally synthesized. It 
is estimated that the number of drugs made from the isolation of natural sources account for 
6% and those coming from derivatives of them is approximately 27% in total (Newman D. J., 
2016). Also, about 27% of drugs are natural mimic molecules and synthetic molecules based 
on the carbon skeleton of natural products. 
During the time frame of 34 years covered from 01/1981 to 12/2014, there were total 1211 
types of medicine have been registered. Their classifications are shown in Figures 11 and 12.  
 
 
Figure 11 : Classification of 1211 types and number of drugs registered worldwide during 
period from 1981 to 2014 (Newman D. J., 2016) 
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As shown in figure 11, which refers only to small molecules, after a significant increase in 
the discovery of new medicines started from 1981 until 1988 with the peak of nearly 70 new 
drugs registered in 1987, the numbers of certified drug per year remain stable from close to 40 
for most of the 1989 to 2000 time frame (except for 1991) then slightly decline to close to 20 
from 2001 to 2010, with the exception of 2002 and 2005, when the figures climbed above 30. 
In the recent four years (2011 to 2014), the numbers showed a sign of rising again from 28 in 
2011 to 44 in 2014 (Newman D. J., 2016). 
If we include also vaccines (V) and biological macromolecule (B) in the statistics then the 
number of approved drugs showed a range from around 20 to just over 50 per year from 1989 
to 2014, particularly in 2012 and 2014 the figures reached 60 and 65, respectively. It should 
be noted that the vaccine data are not complete, so the overall numbers could increase. 
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Major categories of sources: 
N: Unaltered natural product 
B: 
Biological macromolecule – usually a large protein or large peptides ( > 
50 residues) 
ND: Natural product derivative 
NB: Botanical drug 
S: Synthetic drug 
S*: Made by total synthesis, the pharmacophore is from a natural product 
S/NM: Natural product mimic synthetic drug 
S*/NM: Synthetic drugs based on natural product skeleton mimic natural pathway 
V: Vaccine 
 
Figure 12 : Classification of 1562 types and number of drugs registered worldwide during 
period from 1981 to 2014, including also vaccines (V) and biological macromolecule (B) 
(Newman D. J., 2016) 
 
2.2. The origin of cancer drugs  
As of 2016, there were 246 anticancer agents being provided in the market worldwide in 
which up to about 80% of them are drugs originated or related to natural products and only 
19% being from total synthesis (Figure 13).  
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Figure 13 : Classification and number of anticancer agents certified worldwide annually 
from 1940s until 2014 (Newman D. J., 2016) 
 
From the antitumor area perspective, there was a significant aspect in the recent six years 
with a constant increase of approved drugs ranged from 6 to over 10 per year from 2009 to 
2014 (except for 2013). This number promises more anticancer drugs with stronger effects as 
well as a broader treatment ability will be developed in the near future. 
 
2.3. Overview of anticancer agents worldwide 
2.3.1. Anticancer agents from plant 
Some of these agents are shown in Figure 14. 
One of the very well-known anticancer agents is the alkaloids isolated from Madagascar 
periwinkle, the Catharanthus roseus G. Don. species including Vinblastine and Vincristine 
(Guéritte F., Fahy J., 2005), especially, these molecules can also be isolated from the 
symbiotic fungi on this plant (Yang X., 2004).  
Some other compounds with similar structure like Vinorelbin and Vindesin were semi-
synthesised. These molecules act through a mechanism that inhibits tubulin polymerization. 
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Most of the time, other anticancer drugs are used in combination with these molecules in 
treating different types of cancer such as leukemia, testicular cancer, breast cancer, lung 
cancer or Kaposi’s sarcoma (Cragg G. M., 2009). 
 
 
Figure 14 : Examples of plant-derived anticancer agents (Newman D.J., 2016) 
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Etoposide, etopophos and teniposide are semi-synthetic derivatives of the natural product 
epipodophyllotoxin (Lee K. H., 2005), an isomer of podophyllotoxin which was isolated as an 
active antitumor agent from the root of various species of genus Podophyllum. Recently, an 
endophytic fungus isolated from P.peltatum has been found to be a source to produce 
Podophyllotoxin (Eyberger A. L., 2006). Etoposide and Teniposide are effective agents in 
clinical treatment of lymphonas, bronchial and testicular cancers. The mechanisms of these 
molecules based on inhibiting topoisomerase II, an enzyme involved in the replication 
pathway of Deoxyribonucleic acid - DNA during cell cycle progression (Cragg G. M., 2009). 
Taxanes and camptothecins are chemotherapeutic agents derived from natural products 
and have very strong cytotoxic effects. Paclitaxel (Taxol®) was mainly isolated from the bark 
of the Pacific yew, Taxus brevifolia Nutt. (Kingston D. G. I., 2005). This molecule, along 
with some other key precursors (the baccatins), also exists in the leaves of many different 
species such as European’s and some Vietnam’s yews. A significant amount of baccatins 
were then semi-synthesized to paclitaxel and other bioactive analogues, for example docetaxel 
(Taxotere®). Notably, Taxol® has also been isolated from many endophytic fungi (Strobel G., 
2004), however, these fungi have not been developed to be a sustainable source (Cragg G. M., 
2009). Paclitaxel is utilized in the treatment of breast, ovarian, non-small cell lung cancer and 
Kaposi’s sarcoma; meanwhile, docetaxel is mainly used in the treatment of breast and non-
small cell lung cancer. 
Topotecan (Hycamptin®) and Irinotecan (Camptosar®; CPT-11) are semi-synthetic 
derivatives from camptothecin which was isolated from Chinese ornamental tree 
Camptotheca acuminata Decne. (Rahier N. J., 2005). Camptothecin also reported to be 
produced by an endophytic fungus of the family Phycomycetes (Amna T., 2006), this species 
is isolated from the bark of Nothapodytes foetida (Puri S. C., 2005). Although camptothecin 
has been excluded during clinical stage since 1970s by the United States National Cancer 
Institute (NCI) due to its toxicity with bladder, the studies on its derivatives have been 
conducted widely. Two derivatives Topotecan and Irinotecan have stronger effects and 
exhibit low toxicity. Topotecan is used in the treatment of ovarian and small cell lung cancers, 
Irinotecan in the treatment of colocteral cancer. The mechanism for these agents of this class 
is to inhibit topoisomerase I, a key enzyme related to the replication of DNA during cell cycle 
progression (Cragg G. M., 2009).  
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Other plant-derived agents are homoharringtonine, flavopiridol and combretastatins. 
Homoharringtonine was isolated from Chinese plant Cephalotaxus harringtonia (Itokawa H., 
2005). A racemic mixture of harringtonine and homoharringtonine was tested successfully in 
treating acute and chronic myelogenous leukemia. Flavopiridol is a total synthesis compound, 
however, its flavonoid basic structure is based on rohitukine, a flavonoid which has anti-
inflammatory and immunomodulatory bioactivities, isolated from species Dysoxylum 
binectariferum Hook. f. (Meliaceae). Flavopiridol has been going through clinical trials for 
treating different types of cancer such as acute leukemia (Byrd J. C., 2005). The 
combretastatins (for example: combretastatin A4) were isolated from the South Africa bush 
Combretum caffrum during 1970s in the collaboration program between NCI with National 
Botanical Research Institute of South Africa (NBRI) (Pinney K. G., 2005). Combretastatin 
A4, a water soluble derivative, could be a promising agent against thyroid cancer. 
 
2.3.2. Anticancer agents from marine organisms 
Some of these agents are shown in Figure 15 next page.  
Ocean habitat promises to be an abundant source for anticancer agents. Recently, many 
compounds with significant anti-tumor activity have been detected from ocean such as 
Ecteinascidin 743 (Et743) and Aplidine which are very well-known anticancer agents and 
being provided widely in American and European market.  
Although isolated at very low quantity from the ascidian Ecteinascidia turbinate 
(Henriquez R., 2005), the yield of ET743 is enough for pre-clinical and clinical research then 
can be harvested through large-scale aquaculture the species E. turbinata, but later, supplies 
were obtained by a 21-step semi-synthetic conversion from cyanosafracin B, a metabolic 
compound isolated from the marine microbe Pseudomonas fluorescens. Ecteinascidin 743 has 
been approved in Europe for sarcoma treatment since the end of 2007, and has also been 
under clinical trial in treating ovarian, soft tissue sarcoma, breast, endometrial, prostate, non-
small cell lung and pediatric cancer (Cragg G. M., 2009). Ecteinascidin 743 is the first 
compound of a novel class of DNA-binding agents which has transcription-targeted 
mechanism (Henriquez R., 2005). 
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Figure 15 : Some marine organisms-derived anticancer agents (Cragg G. M., 2009) 
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Aplidine (dehydrodidemnin B) is isolated from the Mediterranean tunicate Aplidium 
albicans and has been going through clinical trial phase II in some cancer treatment such as 
melanoma, pancreatic, small cell, non-small cell lung, prostate cancer and acute 
lymphoblastic leukemia (Henriquez R., 2005). The mechanism of this molecule remains 
unclear until now. Halichondrin B is isolated from several sponges, for example: Halichodria 
okadai from Japan (Yu M. J., 2005). The yield is enough for pre-clinical and clinical trials 
and it is obtained through the isolation progress from species Lissodendoryx sp., which is 
aquacultured at large-scale in some deep water regions of New Zealand. The succesful stategy 
to synthesize Halichodrin B and norhalichodrin B was utilized to synthesize other analogs 
with simpler structure which are more stable. Among those, E7389 was selected for drug 
development and has been in pre-clinical trial phase III against refractory breast cancer (Yu 
M. J., 2005). 
Bryostatins are a series of macrocyclic lactones originally isolated from the bryozoan 
Bugula neritina (Hale K. J., 2002; Newman D. J., 2005). Due to some side effects when used 
as single agent, bryostatins are expected to get better when used in combination with some 
other anticancer agents such as alkaloids isolated from periwinkle. Many extensive studies 
have been conducted to synthesize simpler analogs with better bioactivity. These efforts have 
resulted in the synthesis of bryologs, this series have even better bioactivities than bryostatin 
1 in in vitro tests (Wender P. A., 1998, 1999, 2002, 2003). 
While clinical trials of dolastatin 10 had been cancelled, several derivatives of dolastatin 
were progressed through clinical development (Flahive E., 2005). The synthetic compound 
TZT-1027 (auristatin PE or soblidotin) has been going through clinical phase II (Shimoyama 
T., 2006). The analog cematodin (LU-103793) was in clinical trial phase II against malignant 
melanoma, metastatic breast cancer and non-small cell lung cancer and still show no side 
effect (Flahive E., 2005). Clinical studies phase II against breast and non-small cell lung 
cancer are also conducted with ILX651 (synthadotin and tasidotin), a third derivative 
generation of dolastatin. Interestingly, dolastatins are proved to be origin from micro-
organisms with the proof is the isolation of symplostatin 1 from the marine cyanobacterium 
Symploca hynoides (Flahive E., 2005) following by the reports of peptides with similar 
structure of dolastatins from the ubiquitous cyanophyte Lyngbya majuscula (Flahive E., 
2005). 
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2.3.3. Anticancer agents from microbial sources 
Antitumor antibiotics include members of anthracyclin and bleomycin which are very 
important anticancer agents. Some of these agents are shown in Figure 16. 
 
 
 
Figure 16 : Some microbial-derived anticancer agents (Cragg G.M.; Newman D.J., 2013) 
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Anthracyclin is an important class of microbial-derived agents, therein daunorubicin and 
its analogs doxorubicin (adriamycin) are effective anticancer agents used, among others, in 
breast cancer treatment (Arcamone F., 2005). The analogs of doxorubicin such as epirubicin, 
idarubicin, pirirubicin and valrubicin are certified for clinical use and the extent effect of 
doxorubicin is being studied through targeted delivery techniques (Arcamone F., 2005). 
Another important class is the glycopeptolide antibiotics known as bleomycin (for example 
bleomycin A2, Blenoxane
®) (Hecht S. M., 2005). Bleomycin is believed to impact on DNA 
cleavage but recently researches show that the major mechanism of action could be the 
inhibition of t-RNA (Transfer-Ribonucleic acid). The major reason for epothilone researches 
is that these epothilones were active against paclitaxel-resistant cell lines. Ixabepilone is 
synthesized by Bristol-Myers and approved in 2007. Epothione B (patupilone), epothilone D 
(KOS-862) and ZK-EPO have been under clinical trials (Cragg G. M., 2009). 
Until now, the difficulty of culturing naturally occurring micro-organisms is the major 
obstacle in studying biology and chemistry of micro-organisms. It has been estimated that less 
than 1% of micro-organisms seen microscopically have been cultivated. However, the number 
of highly effective agents isolated from them is very impressive. It confirms the potential of 
an enormous untapped resource for drug discovery (Cragg G. M., 2009). 
 
2.4. Vision of the development of natural-derived anticancer agents 
Naturally-derived compounds may have selective bioactivities and may act on specific 
targets. Among the different mechanisms of naturally-derived anticancer agents, interaction 
with tubulin has been one of the most common, more than 25% of anticancer agents being 
considered to be related with it. Examples of different targets of several anticancer drugs in 
the cell cycle are shown in Figure 17. 
In previous natural products researches, new compounds were mainly isolated randomly 
or through biological activity screening such as antibiotic or cytotoxicity. Nowadays, 
developed countries have created new drug generations that are discovered and isolated 
through powerful genetic screening and biochemistry methods which allow scientists to 
identify more accurately compounds containing the desired bioactivities in different extracts. 
Further, these tests can provide precious preliminary data on the mechanism of action of these 
molecules need to validate the early steps of the drug discovery process.  
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Figure 17 : Cell cycle targets of some natural-derived anticancer agents (Meijer L., 2003) 
 
In addition to the “real” biological screening, a new method called “virtual” in silico 
screening has recently occurred. This method utilizes the advance in informatic technology to 
screen virtually new compounds expected to have high bioactivities from a huge database. 
The advantage of this approach is to minimize the cost and time in drug discovery and 
development process. Normally, it consumes 800 million euros and 10 to 15 years to put a 
new drug into circulation with conventional methods, meanwhile, with the modern computer 
systems (for example: computer network – grid), millions of structures could be virtually 
screened just within a few weeks. WISDOM (World-wide In Silico Docking on Malaria) 
could be named as a representative example for this method, the project uses grid for virtual 
screening and anti-malarial drug development on the computer network worldwide. In the 3 
years of the project from 2007 to 2010, hundreds of millions of compounds had been screened 
and dozens of them were processed to test in vitro and then in vivo. 
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3. Vietnamese natural products as sources of anticancer agents 
3.1. Potential of Vietnamese plant sources 
Vietnam territory is located in the tropical monsoon climate, up to three fourths of its area 
are forests and mountains and terrain dissected, therefore the climate condition is varied with 
many characteristic sub-climates. These factors have made the flora of Vietnam become very 
diverse, rich and colorful. According to Professor La Dinh Moi, the number of vascular plants 
in Vietnam is ranging from 12,000 to 13,000 species. In 1998, Phan Ke Loc had estimated 
total 10,386 species (including 733 species only found in cultivation) belonged to 2257 genera 
and 305 families. By 2002, there were additional 13 genera, 222 species and 30 taxons 
discovered and described. 
Statistics showed that, within 50 years the number of plants used for medicinal purpose 
has increased rapidly (Moi L. D., 2005), for example: 
- In 1952: only 1,350 medicinal plants were identified in all three Indochina countries. 
- In 1986:  there were 1,836 medicinal plants were counted in Vietnam. 
- In 1996: the number raised up to 3,200 species. 
- By 2005: it is estimated about 4,000 species were discovered. 
For a long time ago, ethnic communities of Vietnam, especially the residents living on the 
high mountain – remote areas, have known to use herbs as medicines and health care for 
themselves. Many remedies are being circulated among the mountainous ethnic communities 
and each ethnic has its own special prescriptions and herbs. Until now, there are still many 
medicinal plants that modern science does not yet known. According to the preliminary 
statistics of Vietnam Ministry of Health, there were about 39,813 prescriptions and traditional 
remedies identified in Vietnam until 2005 (http://moh.gov.vn/pages/index.aspx; Moi L. D., 
2005). 
The advantage of traditional medicine (oriental medicine) is to strengthen immunity, 
harmonize yin and yang, viscera. However, its ability to inhibit tumor is still limited, in 
comparison with modern medical approaches. The modern medicine with surgery, 
radiotherapy, chemotherapy can have rapid and significant effects on tumors, however, it 
contains many side effects. Thus, the combination of Eastern and Western medicine will 
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promote strengths to overcome weakness in cancer treatments better than themselves alone. 
The interest of combining traditional medicines with modern medicine in cancer treatment has 
been highlighted through the following points: 
- The use of traditional medicines before and after tumor removal surgery increase 
health recovery process. 
- Traditional medicines can increase the susceptibility of the tumors to chemotherapy 
and radiotherapy and also reduce side effects of these methods. 
- Oriental medicines can strengthen the immunity, reduce complications, the risk of 
metastasis and improve the life quality of cancer patients. 
- Some prescriptions can directly inhibit the growth of cancerous cells. 
From the factors above, it can be concluded that the treasure of medicinal plants in 
Vietnam is very abundant and diverse. It is worthwhile to carry out serious researches to find 
out bioactive compounds from remedies and their mechanisms. For example, according to a 
collaboration between scientists in Vietnam Academy of Science and Technology (VAST) 
and The Ohio State University during period 2008 to 2011, there were 824 plants 
corresponding to 398 species studied, from which 17 new and 42 known compounds were 
found to have in vitro activity in one or more bioassays, exhibiting promising IC50 values 
(Perez L. B., 2014). 
However, these types of study are still limited and there are many opportunities for 
scientists to conduct more researches in this field. The obtained results will provide a 
scientific insight and clarity about oriental medicines, contribute to the development of drugs 
in serving for cancer treatment. 
 
3.2. Potential of Vietnamese marine sources 
Vietnam’s sea belongs to the Pacific Ocean, where the biodiversity resources are 
abundant. With about 3,260 km of coastline and more than one million km2 area of the sea, 
Vietnam owns one of the largest natural asset in the world. There are approximately 11,000 
species that have been recorded so far in Vietnam’s marine and coastal including 2,458 
species of fish, 653 species of sponges, 650 seaweeds and so on. Besides providing a huge 
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source of organisms, Vietnam’s sea offers also endless natural compounds for research and 
development of new drugs.  
In recent decades, there have been several intensive researches on marine natural 
compounds carried out by Vietnamese scientists including national projects and especially 
some international collaboration programs with Russia, South Korea, Italia. As a result, there 
were a lot of marine natural compounds isolated and structure determined, some of them were 
recorded as new compounds. Based on the biological activity oriental method, samples which 
were likely to contain bioactive substances, have been selected for further studies and many of 
them yielded positive results, such as:  
- From KC09.15 National research project: 405 samples belonging to 134 marine 
species along the Vietnam’s coastal were collected and conducted to chemical and 
biological researches. The results obtained showed that 4 new compounds were 
discovered and 105 samples exhibited cytotoxicity in which 50 of them were cytotoxic 
to multi-cancer cell lines. One functional food named SALAMIN was developed in 
supporting for cancer treatment (Long P. Q., 2009). 
- From KC09.09/06-10 National research project: 101 marine samples were collected 
focus on coral, sponge and echinoderm species: 43 samples showed cytotoxicity on 
cancerous cells, and 59 compounds isolated in which 12 were new substances (Long 
P. Q., 2009). 
However, due to difficulties in collecting samples, preservation and the very small content 
of bioactive compounds obtained, the study of screening and isolating bioactive substances 
from marine organisms is still very limited and not worth the resources potential. 
 
3.3. Potential of Vietnamese microbial sources 
Study on microbiology in Vietnam have been started from 1960 at some leading 
institutions and universities including National Institute of Science and Technology, Hanoi 
University, Food Industry Research Institute, University of Agriculture and Hanoi University 
of Technology. The yield of these studies is very diverse and covers several main topics such 
as production of biomass and microbial spores, enzymes (native and recombinant), bioactive 
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compounds and microbial biodiversity for various applications in agriculture, industry, 
healthcare and environment. 
As an agriculture country, since 1993, Vietnam government has implemented priority 
policy for science and technology development in which biotechnology is one of the key 
fields. In this case, the microbial gene management policy was requested. In 1997, Vietnam 
Ministry of Science and Technology (MOST) issued Art 2117 for bio-resource management 
(including plants, animals and microbes). Up to date, there are 8 culture collections of 
microbes maintaining 18,000 microbes mainly isolated from Vietnam (fungi, yeasts, bacteria, 
actinomycetes, micro algae and virus). According to statistics from several international 
collaboration and national projects conducted by Vietnam Academy of Science and 
Technology with Germany, Russia …, there were some bioactive compounds which exhibit 
cytotoxicity to cancerous cells discovered during the researches, for example:  
- In the framework of the international collaboration project between Vietnam and 
Russia (2006 - 2008): 5 bioactive compounds were isolated from fungi 
Basidiomycetes, located in the mountainous areas, these subtances exhibited both anti-
oxidant, antibiotic and cytotoxic activities (Long P. Q., 2009). 
- From the national project on fundamental research carried out by Institute of Natural 
Products Chemistry (INPC) during the period 2007 – 2008: 104 parasitic strains were 
isolated from six medicinal plants, 5 compounds had their structure determined and 
showed positive results on cytotoxic test on several cancer cells (Long P. Q., 2009). 
In conclusion, the results obtained above are still very limited and represent a first step for 
the research on compounds of microbial origine in Vietnam. Therefore, this field remains full 
of potential for scientists to conducted more researches in searching for anti-cancer 
compounds in the future.  
 
4. Targeting mortalin – p53 interactions as an anti-cancer 
strategy 
Among the innovative approaches developped in the past decade in drug discovery, 
targeting protein-protein interactions has emerged as a potent strategy in oncology (Ivanov A. 
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A., 2013). In this field, efforts have been made to search for small molecules which inhibit the 
interaction between p53 and proteins which negatively the tumor suppression functions of 
p53. Promising results have been obtained with inhibitors of the interaction between p53 and 
the ubiquitin ligase MDM2 which are currently tested in phase I trials (Andreeff M., 2016)  
With a similar aim, finding inhibitors of chaperone proteins of p53 represents a 
challenging approach. Mortalin is a stress chaperone of Hsp70 family of proteins that 
performs various functions related to proliferation, mitochondrial biogenesis, chaperoning and 
stress response (Renu W., 2002; Sunil C. K., 2007). Mortalin binds to p53 tumor suppressor 
protein and sequesters it in the cytoplasm, resulting in an inhibition of the transcriptional 
activation and control of centrosome duplication functions of p53, thus causing lifespan 
extension of normal human cells and increase malignant properties of human cancer cells 
(Kaul S. C., 2005; Lu W-J., 2011; Vaishnavi K., 2012; Grover A., 2012). It is expected that 
the abrogation of mortalin-p53 interaction will reactivate p53 function. This could represent 
an original anticancer therapeutic approach. 
In recent studies, small molecules, some of natural origin, have been identied as inhibitors 
of p53-mortalin interactions (Utomo D. H., 2012; Grover A., 2012). Further, it has been 
demonstrated that mortalin is associated with liver cancer for which it could be used as a 
marker to predict its early tumor recurrence (Xin Y., 2008). 
We thus wished to answer to the questions : 1) could Vietnamese natural products be 
identified as inhibitors of mortalin – p53 interaction ?, and – 2) if yes, could these molecules 
display pharmacological activity against hepatocellular carcinoma. 
 
5. Overview of virtual screening in drug discovery 
It is a fact that the traditional drug discovery is a time-consuming and very expensive 
process. It has been estimated that for a drug cycle from literature through clinical trials and 
then to the market will need from 10 – 15 years and around 800 million US dollars (Song 
C.M., 2009). In the early 1990s, there were some efforts to find new technologies in the field 
of combinatorial chemistry and high-throughput screening (HTS) in order to shorten the drug 
discovery process by enabling huge libraries of compounds to be synthesized and screened in 
short periods of time. However, these inventions did not give as many positive results as 
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expected. Many of identified potential compounds (hits) were reported to fail in the 
optimization process due to absorption, distribution, metabolism, excretion and toxicity 
(ADME/Tox) deficiencies (Kennedy T., 1997; Venkatesh S., 2000; Hou T., 2004). Therefore, 
searching for new strategies that could help to choose appropriate compounds and limit the 
use of a significant amount of resources is an important objective for the scientists.  
The first time the term “Virtual Screening” (VS) appeared in a peer-reviewed publication 
was in 1997 and since then it has developed rapidly in pharmaceutical research (Lavecchia, 
2013). Virtual screening is a powerful technique for identifying hit molecules as starting 
points for medicinal chemistry. It is usually described as a step by step method with a cascade 
of sequential filters able to narrow down and choose a set of lead-like hits with potential 
biological activity against intended drug targets. The compounds studied do not necessarily 
exist, and their "testing" does not consume valuable substance material. Taken to its extreme, 
any molecule can, in theory, be evaluated by VS. Depending on the intended follow-up, 
databases for VS contain up to 10 million available compounds and this number can be 
handled in one VS experiment. 
Starting from the first algorithm program namely UCSF Dock using computational 
method (Irwin D. K., 1982), many other systems have been introduced, including: Gold 
(Gareth J., 1997), Dock (Ewing T. J., 2001), Glide (Thomas A. H., 2004; Richard A. F., 
2004), FlexX (Bernd K., 1999), AutoDock (Oleksandr V. B., 2002). 
 
Software 
Free for 
Academia 
Website 
AutoDock Yes http://autodock.scripps.edu/ 
Dock Yes http://dock.compbio.ucsf.edu/ 
FlexX No http://www.biosolveit.de/flexx/ 
Glide No http://www.schrodinger.com/ 
Gold No http://www.ccdc.cam.ac.uk/products/life_sciences/gold/ 
EADock  
http://lausanne.isb-
sib.ch/agrosdid/projects/eadock/eadock_dss.php 
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Surflex No http://www.tripos.com/index.php 
ICM No http://www.molsoft.com/docking.html 
LigandFit No http://accelrys.com/products/discovery-studio 
eHiTS No http://www.simbiosys.ca/ehits/index.html 
SLIDE 
Yes on 
demand 
http://www.bch.msu.edu/~kuhn/software/slide/index.html 
ROSETTA_DOCK 
Yes on 
demand 
http://rosettadock.graylab.jhu.edu/ 
Virtual Docker No http://www.molegro.com/mvd-product.php 
Ligand_Receptor 
Docking 
No http://www.chemcomp.com/software-sbd.htm 
FRED 
Yes on 
demand 
http://www.eyesopen.com/oedocking 
ZDOCK Yes http://zlab.umassmed.edu/zdock/ 
Table 01 : Example of some commonly used Docking Software (Lavecchia A., 2013) 
 
In the field of molecular modelling, docking is a method which predicts the preferred 
orientation of one molecule to a second when bound to each other to form a stable complex 
(Figure 18). AutoDock is a script driven flexible automated and random search docking 
technique operated by altering the ligand or a subset of ligand with several rotatable bonds to 
predict the binding interaction between small molecules to the known receptor 3D structure. 
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Figure 18 : Simulation of a docking between ligand and protein (Khamis M. A., 2015) 
 
AutoDock uses the Lamarckian Genetic Algorithm and empirical free energy scoring 
function (Morris G. M., 1999) to provide reproducible results for ligands with approximately 
10 flexible bonds. 
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The objective of this thesis was defined to identify Vietnamese natural compounds 
endowed with antiproliferative properties against HCC. As described above, Vietnam 
possesses an enormous potential of sources of natural products together with a long history of 
traditional medicine based on plants. In Vietnam, research on natural products in plant has 
been far more developed than in the marine and microorganism sectors which have attracted 
the attention of scientists only recently. To date, collection and availability of molecules from 
Vietnamese plant remain much higher and richer than those from marine or microorganisms. 
In this context, we therefore found coherent to focus this thesis on the study of natural 
products originated from plants. 
For our purpose, we used the well characterized human cell lines HepG2 and Hep3b 
represent cellular reference models for in vitro pharmacological studies, proven to be well 
adapted for the study of new molecules active on HCC (Qiu G. H., 2015).  
In a first approach of pharmacological screening, we first aim to collect a group of 
Vietnamese natural compounds which are isolated from plants commonly used in traditional 
remedies known for their liver protective properties. The next stage consisted in biochemical 
studies (such as cytotoxicity assays, subG1 and annexin V tests) conducted on the natural 
compounds selected from the primary screening. In addition, because it has been shown that 
natural products can enhance the sensitivity of human HCC cells to the cytotoxic effect of 
doxorubicin, an anthracycline used in HCC treatment (Weiss R. B., 1992; Tam K., 2013), we 
further explored the ability of the potential molecules to enhance doxorubicin cytotoxicity in 
the HepG2 and Hep3b model cell lines. 
In the second approach, we developed a virtual screening strategy to identify potential 
compounds that could abrogate the Mortalin – p53 interaction. The initial step was to create a 
database of all natural compounds isolated/originated from Vietnamese plants and then to 
carry out in silico analysis using computational tools. In the second step, more detailed 
pharmacological studies were conducted on the natural compound identified in order to 
validate it as a potent inhibitor of p53 – mortalin interaction active on HCC.
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1. Plant Material 
All the Vietnamese natural compounds used in this thesis were isolated and their structure 
determined in Institute of Natural Products Chemistry, Vietnam Academy of Science and 
Technology in Hanoi, with a purity of over 97% as measured using HPLC (High-performance 
liquid chromatography). 
All purified compounds were initially dissolved in dimethyl sulfoxide (DMSO) to adjust 
their concentration for use in pharmacological experiments and stored at -20oC.   
 
1.1. Natural compounds from medicinal plants of Vietnam  
The selection and collection of natural compounds to be screened is based on their origine 
from Vietnamese medicinal plants, in particular, from those which are used popularly as liver 
protective or curing hepatocellular carcinoma diseases. According to this criteria, we have 
collected 26 compounds which were divided into 7 separate groups.  
 
1.2. Natural compounds from virtual screening 
Another approach to select and collect samples is based on the creation and availability of 
a Vietnamese plant compounds database which can be screened in a virtual screening for a 
given biological activity (inhibition of mortalin – p53 interaction in the frame of this study). 
Solasonine which was identified as the hit with the highest score among the 354 screened 
molecules was successfully isolated and purified in Vietnam. 
 
2. Virtual Screening 
2.1. Database of Vietnamese natural compounds 
Within the framework of this thesis, we focus on natural compounds which are origined or 
isolated from Vietnamese plants. This database, therefore, was constituted from two main 
sources: Vietnamese literatures including information of more than 100 thesis in the field of 
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natural products and the second is Dictionary of natural products edition 2010 using 
Microsoft Access (Microsoft® Office 2010) (Figure 19). 
 
 
Figure 19 : Organization of Vietnamese database of natural compounds 
 
This process has resulted in a database consist of 354 natural molecules and most of them 
have been tested and shown to possess at least one biological activity. For a given compound, 
various informations are available, as exemplified in Figure 20. 
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Figure 20 : Example of one compound’s information presented in the database 
 
In the next stage, based on the requirement of AutoDock tool, all the molecules underwent 
a preparation process with multiple steps to get ready for virtual screening. Examples of the 
procedure are described in figure 21. 
Firstly, the molecules were manually draw in the form of two – dimension (cdx format) 
then transformed into three – dimension structure (mol2 format) using ChemBioDraw and 
ChemBio3D Ultra version 14.0 (PerkinElmer®). The reason for choosing mol2 as primary file 
type used for docking is this format has the advantage of storing all the necessary information 
for atom features, position and connectivity. Besides, it is also a standardized format that 
many modelling program nowadays can read.  
In the following stage, this database in mol2 format was processed through DG-AMMOS 
program to generate 3D conformations based on distance geometry and optimize theirs 
structures. The final output of this procedure is in mol2 file types also and from this point, the 
molecules are ready for docking. DG-AMMOS is a new tool developed by Maria A. M. et al. 
in 2009 to produce 3D conformations of small molecules using Distance Geometry and 
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Automated Molecular Mechanics Optimization for in silico screening. The advantage of this 
program is that the source code is entirely available to users and it can be applied to libraries 
with a large number of compounds (David L., 2009). 
 
 
Figure 21 : Example of the preparation of Vietnamese database 
 
2.2. Protein preparation 
According to literatures, Mortalin binds to p53 tumor suppressor protein and sequesters it 
in the cytoplasm. This results in an inhibition of the transcriptional activation and control of 
centrosome duplication functions of p53, thus causing lifespan extension of normal human 
cells and increase malignant properties of human cancer cells (Kaul S. C., 2005; Lu W-J., 
2011; Vaishnavi K., 2012; Grover A., 2012). It is expected that the abrogation of Mortalin-
p53 interaction will reactivate p53 function and could become a proposition for cancer 
therapy. 
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2.2.1. Primary Mortalin protein model – PDB ID: 3N8E  
Mortalin is a stress chaperone of Hsp70 family of proteins that performs various functions 
related to proliferation, mitochondrial biogenesis, chaperoning and stress response (Renu W., 
2002; Sunil C. K., 2007). In the previous studies, it has been demonstrated that Mortalin 
associates with liver cancer metastasis and can be used as a marker to predict early tumor 
recurrence (Xin Y., 2008). Some researchers had identified the p53-binding site of mortalin 
resides in the peptide binding domain which matched with 3N8E model (residues 439 – 597; 
downloaded from the Protein Data Bank (PDB) archive). Therefore, we choose this model for 
docking studies (Iosefson O., 2010; Utomo D. H., 2012). 
 
 
Figure 22 : Visualization of Mortalin protein model 3N8E (residues 439 – 597) 
 
2.2.2. Secondary Mortalin protein model – PDB ID: 4KBO 
Besides the p53-binding site of Mortalin as presented above, also we found out that in 
some other publications, there is another possibility that p53 interacts with Mortalin within 
the residues 253 – 282 domain (Kaul S. C., 2001; Kaul S. C., 2003; Grover A., 2012; Nigam 
N., 2015). There is one Mortalin protein model could be the appropriated candidate for our 
study available on the Protein Data Bank, it has the PDB ID: 4KBO. This model contains 
amino acids sequence 54 – 429 therefore we believe it is suitable for carrying out docking 
research with Vietnamese natural compounds database. 
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Figure 23 : Visualization of Mortalin protein model 4KBO (residues 54 – 429) 
 
2.2.3. Primary p53 protein model – PDB ID: 1AIE 
p53 – 53 kDa, the “guardian of the genome”, is a key tumor suppressor protein that 
regulates cell cycle, prevents cancer by inducing apoptosis, activates DNA repair mechanism 
and enhances the activity of p21 (Vaishnavi K., 2012). Loss of p53 function is one of the 
early events in immortalization of human cells (Levine, 1997; Duncan, 2000). It has been 
proven that the mortalin-binding site of p53 located in the carboxyl terminus 312 – 352 
residues, especially, residues 323 – 327 play an important role in the interaction between 
Mortalin – p53 protein (Kaul S. C., 2005; Iosefson O., 2010). For the reasons above, we 
decided to use p53 model – 1AIE: residues 326 – 356 (Protein Data Bank) to be the most 
appropriate target for docking studies. 
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Figure 24 : Visualization of p53 protein model 1AIE (residues 326 – 356) 
 
2.2.4. Secondary p53 protein model – PDB ID: 3D09 
According to a research conducted by Vaishnavi et al. in 2012, there is a possibility the 
interaction between Mortalin – p53 protein could be affected by the binding of compounds 
with two amino acids (aa) Arg 282 and Leu 111 in p53 protein and therefore, contribute to the 
reactivation of p53 functions (Vaishnavi K., 2012). For this reason, we took model 3D09 
which contains residues 96 – 290 (Protein Data Bank) as the second target for researching p53 
model. 
 
 
Figure 25 : Visualization of p53 protein model 3D09 (residues 96 – 290) 
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2.3. Docking using AutoDock 
The organization of our in silico screening study of 354 natural products from Vietnamese 
plants database is shown in Figure 26. 
 
 
Figure 26 : Scheme of virtual screening of Vietnamese natural compounds database on 
targeted protein models for Mortalin (3N8E; 4KBO) and p53 (1AIE, 3D09) 
 
The docking results obtained using AutoDock 4.2.5 and the Graphical User Interface 
program “AutoDock Tools” were used to prepare, run, and analyze the docking simulations. 
The procedure of an Autodock modelling is described below (see Table 02) 
Proteins (3N8E, 4KBO, 1AIE and 3D09) were prepared for docking simulations by 
assigning of partial charges, solvation parameters and hydrogens to the receptor molecule. 
Water molecules were removed from the protein molecule to make it a free receptor. Since 
ligands are not peptides, Gasteiger charge was assigned and then nonpolar hydrogens were 
merged. AutoDock assigns the rigid roots to the ligand automatically saving time as compared 
to manual picking. Atomic solvation parameters were assigned to the receptor using default 
parameters. 
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The grid box was generated around possible ligand-binding site. All the AutoDock 
docking runs were performed in Intel CoreTM i3-2330 CPU @ 2.20 GHz of Sony origin with 6 
GB DDR RAM. 
 
Step Input Output Content 
Files 
preparation 
R.pdb 
R_rigid.pdbqt Rigid part of the receptor 
R_flex.pdbqt Flexible part of the receptor 
L.pdb L.pdbqt  
    
AutoGrid 
R_rigid.pdbqt   
R.gpf  Grid parameters 
 R.glg Grid log file 
 R.*.map Atom-specific affinity maps 
 R.maps.fld Grid_data_file 
 R.d.map Desolvation map 
 R.e.map Electrostatic map 
    
Docking 
preparation 
R_rigid.pdbqt 
L.pdf 
Docking parameters 
R_flex.pdbqt  
L.pdbqt  
    
Docking 
R_rigid.pdbqt 
L.dlg 
Log + coordinates + energies 
R_flex.pdbqt  
L.pdbqt  
L.pdf  
R.*.map  
R.maps.fld  
R.d.map  
R.e.map  
Table 02 : Procedure model of the Autodock visualization (R = Receptor; L = Ligand) 
 
After the docking process complete, the final step is to analyze output results (L.dlg files) 
in order to select potential compounds which have the best binding score and their optimal 
interact positions with proteins. The binding energy was used as the criteria for filtering the 
best candidates. As presented in figure 27, the detail information of the molecules including 
three – dimensional coordinates and docked energies were fully listed in the obtained log file. 
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Major categories of energy: 
Binding energy : The total energy has released during the process of docking 
Final intermolecular 
energy : 
The energy formed by the interaction between ligands and 
protein 
Torsional free energy : The energy in which the molecule loses during being rotated 
Final Internal energy : 
The internal energy of molecule when changing from 
unbound state to bound state 
Inhibition constant, Ki : Theoretical inhibition constant value of the compound 
Figure 27 : Example of a docking result output 
 
The final internal energy of a molecule is determined by taking total internal energy 
exclude for unbond system’s energy. Then, the binding energy (kcal/mol) is calculated 
according to the formula below: 
Binding energy = Final intermolecular energy + Torsional free energy + Final internal energy 
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3. Biological Studies 
3.1. Cell lines and cell culture 
3.1.1 Cell lines 
All biological assays were tested on two human hepatocellular carcinoma cell lines 
HepG2 (ECACC® Catalogue No. 85011430) and Hep3b (ATCC® HB – 8064TM): 
+ HepG2: cell type derived from liver hepatocellular carcinoma of a 15-year--old 
Caucasian male. According to litterature, HepG2 is Mortalin and wild type p53 positive. 
+ Hep3b: cell type derived from liver hepatocellular carcinoma of a 8-year-old Black 
male. Hep3b is Mortalin positive but does not contain p53 protein. 
T75 flasks were used for Hep3b and T25 for HepG2 cell line (Thermo Fisher Scientific). 
Both of them were cultured using Dulbecco’s Modified Eagle’s Medium (DMEM 1X) + 
GlutamaxTM – Low Glucose (Gibco Industries Inc.) supplemented with 10% fetal bovine 
serum (Hyclone) and 100 U/mL penicillin, and 100 μg/mL streptomycin (Sigma) at 37oC in a 
humidified atmosphere with 5% CO2, 95% air and complete humidity. The culture medium is 
renewed every 2 to 3 days. In these conditions, cell doubling time was around 30 hours.  
 
3.1.2. Cell culture 
Once reached about 80% confluency, cells were washed with PBS 1X (Gibco Industries 
Inc.) and detached using 0.05% trypsin/EDTA (Gibco Industries Inc.) using Primo Vert 
microscope (Zeiss) to observe the dispersion of cell layer. Then, the dye exclusion method 
was utilized to measure number of cell in the flask. 
In the last step, sufficient amount of complete growth medium was added with appropriate 
aliquot of cells suspension into new culture vessels to reach the following cultivation ratio: 
- For HepG2 cell line: the sub-cultivation ratio is 1:10 
- For Hep3b cell line: the sub-cultivation ratio is 1:20 
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3.2. Cell viability Assay 
3.2.1. Principle of the MTT test  
The MTT test or 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Sigma 
Co.) was used in this study. The reason for this choice is that MTT assay is one of the most 
used method for measuring cell viability due to its simple and rapid technique. This 
colorimetric test is based on the activity of the mitochondrial enzyme: succinate 
dehydrogenase (SDH) which results in the cleavage of the yellow MTT into the purple 
formazan crystal.  
SDH is a membrane-bound protein that forms part of the citric acid cycle in which it plays 
an important role in the oxidation of succinate into fumarate. It simultaneously forms 
Complex II in the electron transport chain in the mitochondria and with the reduction 
equivalent FADH2 produced from the succinate oxidation reduces ubiquinone into ubiquinol 
which then moves further to Complex III. 
 
 
 
The dye penetrates through cell membrane and accumulates in intracellular level, yellow 
MTT is oxidized by mitochondrial succinate dehydrogenase into purple formazan crystals. 
These crystals are dissolved under the action of DMSO, producing a coloured solution whose 
absorption can be determined using EONTM microplate spectrophotometers (Biotek). This 
reduction only exits in metabolically active cells, therefore, conversion can be directly related 
to the number of living cells. When the agent is compared with the amount of formazan 
produced by control cells, the effectiveness of the agent in causing death of cells can be 
deduced through the production of a concentration-response curve. 
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3.2.2. Technique 
The MTT assay was performed according to the method described by Mosmann, 1983. 
For HepG2 cells: 2 x 105 cells/mL and Hep3b: 1,5 x 105 cells/mL were seeded into 96 well 
plate (SARSTEDT, sterile) to 100 µL per well. The plates were incubated at 37°C for 48 
hours to obtain about 80% confluent cells. Following this phase, compounds prepared at 
different concentrations were filled into the plate. Each compound was tested three times and 
each time in triplicate to reduce the risks of errors.  
 
µM Compound 1 Compound 2 Compound 3 Compound 4 
500             
100             
20             
4             
0,8             
0,16             
0,032             
 
CM+5% 
DMSO 
CM+5% 
DMSO 
CM+5% 
DMSO 
DMSO DMSO DMSO CM CM CM CM CM CM 
Table 03 : Sample organization of a 96-well plate for MTT assay (CM: Culture medium) 
 
Measure in presence of DMSO 100% was used for measuring 0% cell viability. Measure 
in presence of culture medium only was used for determining the viability in absence of 
compound, taken as the reference (100%). Depending on each type of experiment, different 
incubation time will be selected. After the incubation, aspirated culture medium in the plate 
and washed cell with PBS 1X, then, 20 µL of MTT (MTT solution was prepared at 5mg/mL 
in sterile PBS 1X and store away from light) plus 100 µL of DMEM without phenol red were 
added into each well. The plate is shaken (350 rpm) for 20 minutes at room temperature then 
incubated for 3 hours at 37°C in 5% CO2, 95% air and complete humidity conditions. After 
the incubation, add 100 µL of DMSO into each well to dissolve the formazan crystals which 
then take a violet color. The plates were further incubated for 5 minutes at room temperature, 
and the optical density (OD) of the wells was determined using EONTM microplate 
spectrophotometers at a test wavelength of 590 nm and a reference wavelength of 630 nm. 
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The viability of cells is calculated according to formula below: 
Viability (%) = (OD of exposed cells : OD of cell unexposed) x 100 
The half maximal inhibitory concentrations (IC50) were determined using the Graphpad 
Prism software (Graphpad Software, Inc. San Diego, CA, USA). 
 
3.3. Quantitative detection of apoptosis rate  
3.3.1. Principle of the SubG1 test 
This is a method used to detect cells that have lost some of their DNA in late stage of 
apoptosis process following endonucleases activity. Endonucleases degrade DNA in small 
fragments of about 180 bp, which accumulate in the cell. After ethanol fixation and wash with 
a phosphatecitrate buffer, these DNA oligimeres leak out of the cell decreasing the DNA 
content. Using the nucleic acid stain propidium iodide (PI), the number of hypodiploid cells 
undergoing this process can be counted in subG1 region of PI histogram. 
 
3.3.2. Technique 
In the framework of this research, to investigate effect of ent-kaurane family on the 
apoptotic rate, HepG2 and Hep3b cell types were incubated with compound 5 at various 
concentrations for 48 hours (0-2-4-8-16 µM). Cells were seeded at a density of 4 x 105/mL 
into 6-well plates (SARSTEDT, sterile) for Hep3b cell type and 6 x 105/mL into 24-well 
plates (SARSTEDT, sterile) for HepG2. The plates were incubated at 37°C for 48 hours to 
obtain about 80% confluent cells. According to CycleTestTM Plus DNA Reagent kit (BD 
Biosciences), the procedure is carried out in the following steps: 
 
a. Cell suspensions 
+  Cells were washed with PBS 1X and dissociated with Gibco® Cell Dissociation Buffer, 
enzyme free PBS. Next, sufficient amount of complete growth medium were added to each 
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well and brought to centrifuge (500 rpm) at room temperature (20oC - 25oC). Cells were kept 
on ice from this step. 
 
b. Staining 
In this step, cells were stained respectively with Solution A, B and C in accordance to the 
protocol of BDScience before analyzed using the LSRII flow cytometer (BD Biosciences) 
within 1 hour after the staining procedure end. 
 
3.4. Measurement of cell apoptosis using flow cytometry for Annexin V 
3.4.1. Principle of the method 
Apoptosis, or programmed cell death, is a normal physiologic process for removal of 
unwanted cells. The process is characterized by specific morphologic features, including loss 
of plasma membrane asymmetry and attachment, plasma membrane blebbing, condensation 
of the cytoplasm and nucleus, and internucleosomal cleavage of DNA. 
Loss of plasma membrane asymmetry is one of the earliest features of apoptosis. In 
apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is translocated from the 
inner to the outer leaflet of the plasma membrane, thereby exposing PS to the external cellular 
environment. 
Annexin V, a 35-36 kDa Ca2+-dependent phospholipid-binding protein, has high affinity 
for PS, and fluorochrome-labeled Annexin V can be used for the detection of exposed PS 
using flow cytometry. Thus, it can be used for the detection of apoptosis. Also the 
differentiation between apoptotic and necrotic cells can be performed by simultaneous 
staining with Propidium Iodide, the cell membrane integrity excludes PI in viable and 
apoptotic cells, whereas necrotic cells are permeable to PI. Therefore, cells that are considered 
viable are both Annexin V and PI negative, while cells that are in early apoptosis are Annexin 
V positive and PI negative, and cells that are in late apoptosis or already dead are both 
Annexin V and PI positive. 
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Figure 28 : Diagram showing healthy and apoptotic cells with markers for detection of 
apoptosis (from BD Reagents Apoptosis Brochure) 
 
3.4.2. Technique 
The apoptosis process was evaluated using the BD PharmigenTM Annexin V: FITC 
Apoptosis Detection Kit I.  Cells were seeded at a density of 4 x 105/mL into 6-well plates for 
Hep3b cell type and 6 x 105/mL into 24-well plates for HepG2. The plates were incubated at 
37°C for 48 hours to obtain about 80% confluent cells then incubated with various 
compounds as described below: 
- Compound 5 (ent-kaurane family): tested on both HepG2 and Hep3b cell lines at five 
concentrations (0-2-4-8-16 µM) for 48 hours of incubation. 
- solasonine: tested at concentrations of 0-5-7,5-10 µM on HepG2 and 0-2,5-5-7,5 for 
Hep3b at 24 hours of incubation. 
- 3 controls (without compounds) were prepared for this assay including:  
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 Cells without PI and FITC Annexin V solution staining  
 Cells staining with PI solution only 
 Cells staining with FITC Annexin V solution only 
According to the manufacturer’s instructions, the procedure is carried out in the following 
steps:  
 
a. Cell suspensions 
- After the incubation, cells were washed with PBS 1X and dissociated with Gibco® Cell 
Dissociation Buffer, enzyme free PBS. Added sufficient amount of complete growth medium 
to each well and brought to centrifuge (500 rpm) at room temperature (20oC - 25oC). Cells 
were kept on ice from this step. Next, washed cell with cold PBS 1X and centrifuged two 
times before process to staining procedure. 
 
b. Staining 
In this step, cell were stained respectively with Annexin V Binding buffer, FITC Annexin 
V and PI solution in accordance to the protocol of BDScience before analyzed using the 
LSRII flow cytometer (BD Biosciences) within 1 hour after the staining procedure end. 
 
3.5. Sensitization assay of Doxorubicin and ent-kaurane compounds to 
hepatocarcinoma cell lines 
3.5.1. Principle of the assay 
To date, HCC is still a major challenge for medical oncologists due to its highly 
chemoresistant nature and causing a lot of side effects to normal tissues (Llovet J. M., 2005). 
Hence, alternative treatment strategies are urgently needed. Doxorubicin (Dox) is an 
anthracyline antibiotic isolated from Streptomyces peucetius that has been used effectively for 
the treatment of several cancers including: hepatocarcinoma, ovarian, breast and prostate 
(Yang T. S., 2002; Fong M. Y., 2012). Nevertheless, the use of Doxorubicin is limited by 
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severse dose-dependent side effects such as acute nausea, stomatitis, neurological, 
cardiotoxicity and bone aplasia (Fong M. Y., 2012; Fan C. 2014). Due to those problems, 
single-agent chemotherapy is no longer favored for treating HCC and many efforts has been 
made until now to identify chemo-sensitizers which are agents that are able to augment 
efficiency of anticancer drugs and simultaneously overcome multi-drug resistance and side 
effects.  
Recently, studies of combination therapy with Doxorubicin has gained attention (Yang T. 
S., 2002; Kaur K., 2007; Gambari R., 2013; Fan C. 2014). For example: Kaur K. et al. proved 
that Withaferin A enhances the cytotoxic effect of Doxorubicin in an osteogenic sarcoma 
(U2OS) and in breast cancer cell line (MCF-7) using a cell proliferation assay. 
In our study, we evaluated the ability of ent-kaurane compounds to enhance the cytotoxic 
effects of Doxorubicin on HCC cell lines.  
 
3.5.2. Technique 
Both HepG2 and Hep3b cell lines were used to test for the potentiation effects. Cells were 
seeded at concentration 2 x 105 cells/mL for HepG2 and 1,5 x 105 cells/mL for Hep3b cell 
type into 96 well plate (SARSTEDT, sterile) to 100 µL per well. The plates were incubated at 
37°C for 48 hours to obtain about 80% confluent cells before incubated with compounds. 
 
a. Potentiation effects of ent-kaurane compounds with Doxorubicin 
Doxorubicin was used at 4 µM. Cells were incubated with Doxorubicin either alone or in 
combination with compounds 1 to 7 at three concentrations: 2, 5 and 10 µM (except 
compound 3 tested at 20, 50 and 100 µM). Next step, incubated for 24 hours then measured 
using cell viability assay (MTT assay). 
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 Dox alone (4 µM) Dox + Compound  Compound  alone 
2 µM          
5 µM          
10 µM          
 
CM+5% 
DMSO 
CM+5% 
DMSO 
CM+5% 
DMSO 
DMSO DMSO DMSO CM CM CM 
Table 04 : Sample organization of the potentiation experiment of Doxorubicin with ent-
kaurane compounds (CM: Culture medium) 
 
b. Potentiation effect of compound 5 with Doxorubicin 
Cells were incubated with Doxorubicin at various concentrations starting at 500 µM 
followed by serial of 5-fold dilutions down to 0.032 µM either alone or combined with 
compound 5 (CP5), the representative molecule of the ent-kaurane family, at 3 different 
concentrations: 2, 5 and 10 µM. Cells were incubated for 6, 12, 24 and 48h of incubation 
before measured for cell viability using cell viability assay (MTT assay). 
 
µM Dox alone Dox + CP5 (2 µM) Dox + CP5 (5 µM) Dox + CP5 (10 µM) 
500             
100             
20             
4             
0,8             
0,16             
0,032             
 
CM+5% 
DMSO 
CM+5% 
DMSO 
CM+5% 
DMSO 
DMSO DMSO DMSO CM CM CM CM CM CM 
Table 05 : Sample organization of the potentiation experiment of Doxorubicin with 
compound 5 (CM: Culture medium) 
 
3.6. Pifithrin alpha assay 
3.6.1. Principle of the assay 
Pifithrin alpha (PFT-α) [2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-
tolylethanone hydrobromide] is a synthetic, water-soluble and stable compound. It has been 
considered to be a specific inhibitor of p53 and useful for reducing the side effects of cancer 
therapy due to the blockage of p53-dependent transcriptional activation and apoptosis 
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(Komarov P. G., 1999). PFT-α is thus used experimentally in studies aiming at understanding 
p53-dependent apoptotic processes. 
 
3.6.2. Technique 
Cytotoxicity was evaluated using the MTT assay. PFT-α (Sigma) was purchased in white 
crystalline powder and was made up as stock solutions in DMSO (54,4 mmol/L) prior to 
dilution into medium to the required final concentration. Cells were seeded at 2 x 105 
cells/mL for HepG2 and 1,5 x 105 cells/mL for Hep3b cell lines into 96 well plate 
(SARSTEDT, sterile) at the volume 100 µL per well. Plates were incubated at 37°C for 48 
hours to obtain about 80% confluent cells. We performed the experiments at two different 
incubation times (12 and 24 hours) with various concentrations (2.5, 5, 7.5 µM) of solasonine 
alone or in combination with PFT- α at 10, 20, 30 µM. Cells were pre-incubated with PFT-α 
for 1 hour prior adding solasonine. 
 
µM 
solasonine 
alone 
solasonine 
+ 10 µM PFT-α 
solasonine 
+ 20 µM PFT-α 
solasonine 
+ 30 µM PFT-α 
7,5             
5             
2,5             
 10 µM PFT-α alone 20 µM PFT-α alone 30 µM PFT-α alone 
 
CM+5% 
DMSO 
CM+5% 
DMSO 
CM+5% 
DMSO 
DMSO DMSO DMSO CM* CM CM CM CM CM 
Table 06 : Sample organisation of a 96-well plate for PFT-α experiment  
 
After incubation, plates were processed to measure the half maximal inhibitory 
concentration (IC50) value according to the MTT assay protocol presented above. 
 
3.7. Western Blot 
3.7.1. Principle of the method 
Western Blot - WB (immunoblotting or protein blotting) is a powerful technique used in 
cell and molecular biology for detecting specific proteins in a sample of tissue homogenate or 
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extract that are of low abundance. The term “Western Blot” was given to the technique of 
Burnette (Burnette W. N., 1981) which is a procedure slightly modified from the method 
originated in the laboratory of Harry Towbin (Towbin H., 1979).  
This method uses SDS-PAGE (Sodium dodecyl sulfate – Polyacrylamide gel 
electrophoresis) to separate native proteins by three-dimension structure or denatured proteins 
by the length of the polypeptide. Then, the proteins are transferred to an adsorbent membranes 
made of nitrocellulose or polyvinylidene difluoride (PVDF) where they are stained with 
antibodies specific to the target proteins (Towbin H., 1979; Renart J., 1979). 
In the framework of this research, this technique is utilized to prove the existence of 
Mortalin protein in both HepG2 and Hep3b and to investigate the possible mechanisms of 
action of solasonine in HCC cell lines. 
 
3.7.2. Technique 
Cells were seeded at a density of 4 x 105/mL into 6-well plates for Hep3b cell type and 6 x 
105/mL into 24-well plates for HepG2. Plates were incubated at 37°C for 48 hours to obtain 
about 80% confluent cells before incubated with solasonine at different concentrations: 0 – 
2,5 – 5 – 7,5 µM for 24 hours. After incubation, cells were washed with PBS 1X and detached 
using 0.05% trypsin/EDTA (Gibco Industries Inc.): add 1mL/ well for 6-well plate and 0,2 
mL/well for 24-well plate, then incubate at 37oC until cells are dispersed from the flasks 
(usually within 5 to 15 minutes). Add sufficient amount of complete growth medium into 
each well and resuspend carefully then counting cells using hemocytometer in order to 
transfer one million cells into each 15 mL tube. 
 
a. Determining the presence of Mortalin protein 
Total cell lysates of both HepG2 and Hep3b cell lines were collected using lysis buffer 
(NET with 0,5% Triton 100X). Protein concentrations were measured using Pierce® BCA 
Protein Assay Kit (Thermo Scientific) in accordance with the manufacturer’s instructions then 
the cell lysate proteins (50 µg) were separated by 12,5% SDS – PAGE and transferred onto 
nitrocellulose membranes (GE Healthcare) using a semidry Trans-Blot® TurboTM Transfer 
System (Bio-RAD). The blotting membranes were blocked with PBS 1X/0,1% Tween-20 
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containing 10% skim milk for one night at 4oC. Primary antibodies specific for Mortalin (Cell 
Signaling) was diluted at ratio 1:1000 as indicated by the manufacturer and reacted with 
membranes at 4oC for 4 hours. Monoclonal antibody to β-actin (diluted ratio 1:1000; Cell 
Signaling) also used as an internal control. Then, membranes were washed three times with 
PBS Tween Milk and followed by incubation with secondary antibodies anti-rabbit (diluted at 
ratio 1:2000; Cell Signaling) for one hour before washed with PBS Tween. The protein levels 
were analyzed by enhanced chemiluminescence with Supersignal® West Dura Extended 
Duration Substrate Kit (Thermo Scientific). 
 
b. Investigating the apoptotic mechanisms induced by solasonine 
In this assay, we carried out experiment with cell incubated with solasonine at different 
concentrations. Cell lysates including: cytosolic, nuclear soluble and nuclear insoluble 
fractions of both HepG2 and Hep3b cell lines were collected using lysis buffer (Schreiber E., 
1990). Protein concentrations were measured using Pierce® BCA Protein Assay Kit (Thermo 
Scientific) in accordance with the manufacturer’s instructions then the cell lysate proteins 
(400 µg) were separated by 12,5% SDS – PAGE and transferred onto nitrocellulose 
membranes (GE Healthcare) using a semidry Trans-Blot® TurboTM Transfer System (Bio-
RAD). The blotting membranes were blocked with PBS 1X/0,1% Tween-20 containing 10% 
skim milk for one night at 4oC. 
Primary antibodies specific for p53 (diluted ratio 1:800; Life Technology) and p21 
(diluted ratio 1:2000; Cell Signaling) were incubated with membranes at 4oC for 4 hours. 
Then, membranes were washed three times with PBS Tween Milk and followed by incubation 
with secondary antibodies anti-mouse (diluted at ratio 1:2000; Cell Signaling) for one hour 
before washed with PBS Tween. The protein levels were analyzed by enhanced 
chemiluminescence with Supersignal® West Dura Extended Duration Substrate Kit (Thermo 
Scientific). Monoclonal antibody to β-actin (diluted ratio 1:1000; Cell Signaling) also used as 
an internal control for cytosolic fraction, for nuclear soluble and nuclear insoluble fractions 
were PARP (diluted ratio 1:1000; Cell Signaling) and Lamin B1 (diluted ratio 1:1000; Cell 
Signaling) respectively. 
 
Materials and Methods  
 
83 
 
3.8. Statistical analysis 
All experiments were performed at least three times. Value were expressed as mean ± SD. 
Differences were analyzed using the Student’s t-test. Differences with p < 0.05 (*) or p < 
0.001 (***) were considered statistically significant. 
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1. Pharmacological screening of Vietnamese plants database 
1.1. Collecting Vietnamese natural compounds from medicinal plants 
resources 
The collection consisted of 26 natural compounds originated from medicinal plants 
commonly used in traditional prescriptions for liver protective and liver cancer treatment in 
Vietnam. All the compounds were isolated and structure determined in Institute of Natural 
Products Chemistry, Vietnam Academy of Science and Technology with a purity over 97% as 
measured using HPLC (High-performance liquid chromatography). These compounds were 
classified into 7 groups based on their original plants. 
 
1.1.1. Ent-kaurane compounds from Croton kongensis Gagnep. 
This group includes 7 diterpenoids. Croton kongensis Gagnep belongs to Euphorbiaceae 
family, commonly named in Vietnamese as “Kho sam Bac Bo”, is a tropical shrub native to 
Northern Vietnam (Giang P. M., 2003). It has been used commonly in traditional prescription 
to treat leprosy, psoriasis, malaria and genital organ prolapse (Chi V. C., 1997; Giang P. M., 
2003). Ent-kaurane-type diterpenoids were isolated from the leaves of Croton kongensis 
Gagnep. and their structure determined from phytochemical investigations (Minh P. T., 2003; 
Giang P. M., 2004; Kuo P. C., 2007). For some of them, the cytotoxic properties have been 
tested against breast MCF-7, lung A549 (Kuo P. C., 2007), liver SK-HEP1 (Sul Y. H., 2013), 
intestinal Caco-2 and colon LS180 (Thuong P. T., 2014) cancer cell lines. The structure of 7 
studied ent-kauranes are shown in Table 07. 
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No. Name R1 R2 R3 R4 R5 
MW 
(g/mol) 
1 ent-18-acetoxy-7-hydroxykaur-16-en-
15-one (C22H32O4) 
H OAc OH H =CH2 360 
2 ent-1α-acetoxy-7,14α-dihydroxykaur-
16-en-15-one (C22H32O5) 
OAc H OH OH =CH2 376 
3 ent-16(S)-18-acetoxy-7-hydroxykaur-
15-one (C22H34O4)  
H OAc H OH CH3 362 
4 ent-7,14α-dihydroxykaur-16-en-15-one 
(C20H30O3) 
H H OH OH =CH2 318 
5 ent-18α-acetoxy-7α,14-dihydroxykaur-
16-en-15-one (C22H32O5) 
H OAc OH OH =CH2 376 
6 ent-1α,14α-diacetoxy-7-hydroxykaur-
16-en-15-one (C24H34O6) 
OAc H OH OAc =CH2 418 
7 ent-1α,7-diacetoxy-14α-hydroxykaur-
16-en-15-one (C24H34O6) 
OAc H OAc OH =CH2 418 
Table 07 : Structure of diterpenoids isolated from Croton kongensis Gagnep. 
 
1.1.2. Triterpenoids from Syzygium formosum (Wall.) Masam. 
This plant belongs to Myrtaceae family and it has been used for long time as medicine for 
some significant bioactivities such as: liver protective, antibacterial, anti-tumor... (Fujioka T., 
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1994; Huong V. N., 2003; Thanh H. V., 2008; Jaki B. U., 2008) We chose 6 compounds 
isolated from leaves for bioactivities study. Their structures are shown in Table 08. 
 
No. Name Structure 
MW 
(g/mol) 
8 
Betulinic acid (3β-
hydroxy-lup-
20(29)-en-28-oic 
acid) (C30H48O3) 
 
456 
9 
2,3β-dihydroxy- 
lup-20(29)- en-28-
oic acid (C30H48O4) 
 
472 
10 
Corosolic acid 
(2,3β-dihydroxy-
urs-12-en-28-oic 
acid (C30H48O4) 
 
472 
11 
Asiatic acid 
(2,3β,23-
trihydroxy-urs-12-
en-28-oic acid) 
(C30H48O5) 
 
488 
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12 
Oleanolic acid 
(3-hydroxy-
olean-12-en-28-oic 
acid)  (C30H48O3) 
 
 
456 
13 
2,3-dihydroxy-
olean-12-en-28-oic 
acid (C30H48O4) 
 
472 
Table 08 : Structure of triterpenoids isolated from Syzygium formosum (Wall.) Masam. 
 
1.1.3. Flavonoids from Clerodendrum indicum (L.) Kuntze 
Clerodendrum indicum (L.) Kuntze belongs to Verbenaceae family. It is popularly used in 
fever, atrophy, consumption, cough, bronchitis and blindness. Leaves are used as vermifuge 
and tonic. The root is considered useful in asthma, cough and scrofulous affection (Rehman 
A. U., 1997; Rahman M. Z. A., 2000; Shrivastava N., 2007; Raihan S. Z., 2012). The 
structure of 2 compounds Pectolinarigenin and Hispidulin isolated from flower and leave are 
described below (Table 09). 
 
No. Name Structure 
MW 
(g/mol) 
14 
Pectolinarigenin 
(5,7-dihydroxy-6,4’-
dimethoxyflavone) 
(C17H14O6) 
 
314 
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15 
Hispidulin   
(5,7,4’-trihydroxy-6-
methoxyflavone) 
(C16H12O6) 
 
300 
Table 09 : Structure of compounds isolated from Clerodendrum indicum (L.) Kuntze 
 
1.1.4. Compounds isolated from Rubus alceifolius Poir. 
Rubus alceifolius Poir. belong to Rosaceae family commonly found in many provinces in 
Vietnam and other Asia countries. It is a well-known medicinal plant for hepatoprotective 
activity and also efficiency in anti-oxidant, treatment of urologic diseases, diabetes, kidney 
stone (Hong Z., 2010; Zhao J., 2013, 2014, 2015). Table 10 presents the structure of 3 
compounds isolated from root of this plant. 
 
No. Name Structure 
MW 
(g/mol) 
16 
Euscaphic acid 
(2,3,19-trihydroxyurs-
12-en-28-oic acid) 
(C30H48O5) 
 
488 
Results and Discussion  
 
92 
 
17 
Suavissimoside R1 
(28-O-β-D-
glucopyranosyl ester of 
2,3β,19-trihydroxyurs-
12ene-23,28-dioic acid) 
(C36H56O12) 
 
680 
18 
Trachelosperoside A1 
(28-O-β-D-
glucopyranosyl ester of 
2,3β,19-trihydroxyurs-
12ene-24,28-dioic acid) 
(C36H56O12) 
 
680 
Table 10 : Structure of compounds isolated from Rubus alceifolius Poir. 
 
1.1.5. Compounds isolated from Smilax glabra Roxb. 
Smilax glabra Roxb. belong to Smilacaceae family distributed widely in the territory of 
Vietnam and many other Asia countries. In vitro and animal studies have shown that this 
botanical has antioxidant, antiviral, renoprotective, immunostimulatory, anti-inflammatory, 
hepatoprotective and anticancer properties (Kuo Y. H., 2005; Ban J. Y., 2006; Chu K. T., 
2006; Ooi L. S., 2008; Xia D., 2013). Table 11 presents the structure of 2 compounds isolated 
from root of this plant that we have collected. 
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No. Name Structure 
MW 
(g/mol) 
19 
Astilbin  
(2R,3S)-3,3’,4’,5,5,7-
pentahydroxyflavanone-3-
O-L-rhamnopyranoside 
(C21H22O11) 
 
450 
20 
Engeletin  
(2R,3S)-3,5,7,4’-
tetrahydroxyflavanone-3-
O-L-rhamnopyranoside 
(C22H22O10)  
 
434 
Table 11 : Structure of compounds isolated from Smilax glabra Roxb. 
 
1.1.6. Compounds isolated from Sarcandra glabra (Thunb.) Nakai 
Sarcandra glabra (Thunb.) Nakai belongs to Chloranthaceae family is a species 
distributed widely in many regions in Vietnam and South East Asia countries. Laboratory 
studies have shown that it can stop cancer division, reduce side effects of cancer treatment, 
control bleeding disorders and used in traditional Chinese medicine for bone fractures and 
arthritis (Hocking G. M., 1997; Li Y., 2006; Li W. Y., 2007; He X. F., 2010). The structure of 
2 compounds isolated from root of this plant are described in Table 12. 
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No. Name Structure 
MW 
(g/mol) 
21 
2’,6’-dihydroxy-3’,4’-
dimethoxychalcon 
(C17H16O5) 
OHO
O
OH O
2
3
4
5
6
1'
2'
3'
4'
5'
6'



1
 
300 
22 
(2R)-5-hydroxy-6,7-
dimethoxyflavanon 
(C17H16O5) 
 
300 
Table 12 : Structure of compounds isolated from Sarcandra glabra (Thunb.) Nakai 
 
1.1.7. Compounds isolated from Hydrangea macrophylla (Thunb.) Ser. 
Hydrangea macrophylla (Thunb.) Ser. is a species of flowering plant in the family 
Hydrangeaceae. Many studies have proven this plant has anti-allergic, anti-malarial and anti-
microbial properties and also hepatoprotective activity by suppression of D-galactosamine-
induced liver injury (Yoshikawa M., 1996; Kamei K., 2000; Nakagiri R., 2003; Zhang H., 
2009). Table 13 (next page) shows 4 compounds isolated from different parts of this plant. 
 
 
 
 
 
 
Results and Discussion  
 
95 
 
No. Name Structure 
MW 
(g/mol) 
23 
Phyllodulcin  
(3R)-3-(3’-hydroxy-4’-
methoxyphenyl)-8-
hydroxy-
dihydroisocoumarin 
(C16H14O5) 
 
331 
24 
Thunberginol I  
(3R)-3-(3-methoxy-4-
hydroxyphenyl)-8-
hydroxydihydroisocumarin 
(C16H14O5) 
 
286 
25 
Hydrangenol  
(3S)-3-(4-hydroxyphenyl)-
8-
hydroxydihydroisocumarin 
(C15H12O4) 
 
301 
26 
(+) -Hydrangenol 4’-O-
Glucoside  
(3S)-3-(4-hydroxyphenyl)-
8-
hydroxydihydroisocumarin
-4’-O-Glucoside 
(C21H23O9) 
 
463 
Table 13 : Structure of compounds isolated from Hydrangea macrophylla (Thunb.) Ser. 
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1.2. Biochemical study of Vietnamese natural compounds 
1.2.1. Cytotoxic effects of 26 natural compounds on hepatocarcinoma HepG2 and 
Hep3b cell lines 
All 26 natural compounds in our database have been tested on two hepatocarcinoma 
HepG2 and Hep3b cell lines to check for their cytotoxicity effects. The IC50 results are shown 
in Table 14. 
 
Compound 
24 hrs 48 hrs 72 hrs 
HepG2 Hep3b HepG2 Hep3b HepG2 Hep3b 
1 8.3 ± 1.5 8.0 ± 0.6 3.6 ± 1.5 8.6 ± 0.4 3.8 ± 0.8 3.4 ± 0.2 
2 11.2 ± 5.1 9.9 ± 1.2 9.6 ± 3.1 8.5 ± 0.7 5.8 ± 0.9 4.8 ± 0.4 
3 98.6 ± 25.4 116.2 ± 41.6 85.2 ± 32.5 69.6 ± 13.9 116.9 ± 18.9 99.4 ± 10.2 
4 8.4 ± 1.8 7.8 ± 2.3 3.9 ± 0.3 6.1 ± 0.5 3.9 ± 0.1 3.8 ± 0.2 
5 3.1 ± 0.5 9.0 ± 0.4 3.5 ± 0.8 3.7 ± 0.1 3.2 ± 0.2 3.7 ± 0.4 
6 5.7 ± 1.2 9.5 ± 0.5 5.0 ± 1.2 6.1 ± 0.5 4.2 ± 0.1 5.3 ± 0.5 
7 12.1 ± 3.9 16.1 ± 5.8 13.7 ± 1.3 9.7 ± 0.1 14.1 ± 2.2 15.5 ± 0.6 
8 97.6 ± 26.2 168.9 ± 20.8  104.0 ±  25.8  67.9 ± 30.5 25.6 ± 14.2 31.2 ± 0.8 
9 33.1 ± 8.1 59.9 ± 13.0 24.0 ± 3.3 39.1 ± 12.5 25.9 ± 2.8 25.9 ± 0.8 
10 39.3 ± 4.3 52.3 ± 1.3 47.2 ± 4.1 42.7 ± 4.8 50.3 ± 3.2  44.9 ± 1.5 
11 29.6 ± 5.9 52.0 ± 1.8 23.4 ± 6.0 32.2 ± 8.3 20.7 ± 4.3 21.5 ± 3.5 
12 > 500 123.3 ± 8.6 192.4 ± 65.0 118.3 ±20.8 230.9 ± 57.3 120.8 ± 4.7 
13 101.3 ± 24.3 57.9 ± 22.1 105.0 ± 18.0 83.3 ± 11.2 87.3 ± 12.8 50.9 ± 2.1 
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14 94.2 ± 40.1 108.4 ± 22.3 171.15 ± 43.3 113.4 ± 4.5 95.0 ± 51.1 56.5 ± 3.3 
15 215 ± 24.6 90.9 ± 15.9 106.8 ± 24.6 67.2 ± 12.9 129.4 ± 18.1 84.4 ± 3.5 
16 > 500 > 500 204.2 ± 62.7 > 500 247.8 ± 72.2 285.3 ± 5.6 
17 > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
18 > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
19 > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
20 > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
21 49.3 ± 9.5 93.3 ± 18.9  49.5 ± 3.1 70.1 ± 12.8 48.1 ± 3.5 60.6 ± 7.0 
22 > 1000 > 1000 > 1000 > 1000 > 1000 > 1000 
23 > 500 > 500 > 500 > 500 > 500 > 500 
24 > 500 > 500 > 500 > 500 > 500 > 500 
25 > 500 > 1000 > 1000 > 1000 > 1000 > 1000 
26 > 500 > 1000 > 1000 > 1000 > 1000 > 1000 
Doxo 50.8 ± 3.3 49.3 ± 17.3 26.5 ± 1.8 25.1 ± 2.1 29.0 ± 1.8 28.1 ± 1.4 
Table 14 : Cytotoxic activity (IC50, µM) of 26 Vietnamese natural compounds on human 
HCC HepG2 and Hep3b cell lines after 24 – 48 – 72 hours of incubation. Doxorubicin was 
used as positive control. Results are expressed as the mean ± SD values from three 
independent experiments. 
 
Among the 26 tested compounds, 17 compounds exhibited a cytotoxic effect (IC50 < 500 
µM) against HepG2 and Hep3b cell lines with no significant difference between these two 
cell types. We divided the bioactive molecules into 3 groups depending on their activity (IC50) 
and their chemical structures. Firstly, the diterpenoids family (compounds 1 to 7) was 
identified as the strongest cytotoxic group with most of the IC50 values lower than 10 µM 
except compound 3 with the toxicity 8 to 10 fold lower due to structure different (see detailed 
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analysis in following paragraph 1.2.2.). The second group included compounds 8 to 13 and 16 
classified into two main skeletons: Lupane and Ursane (Figure 29) 
 
    
        Lupane Skeleton                      Ursane Skeleton 
         (Compounds 8 and 9)          (Compounds 10,11, 12, 13 and 16) 
Figure 29 : Lupane and Ursane skeletons 
 
Most of the cytotoxicity values of these compounds ranged within 50 – 100 µM values 
(except compound 16), depending on the incubation time. Within a given group of 
compounds, the difference observed in their activity could be correlated with their structural 
difference. When comparing compounds 8 and 9, compound 9 exhibited a higher cytotoxicity 
due to the OH group at position 2. This group helps in increasing the bioactivity and also 
making the compound more soluble. Regarding compounds 10, 11, 12, 13 and 16, the higher 
cytotoxicity of compound 11 may be explained by the presence of an OH group at position 
23, making the molecule more reactive and more soluble than the other related compounds. 
The three other active compounds 14, 15 and 21 were arranged into a third group (the 
flavonoids) in which it was difficult to establish a correlation between their activity and their 
structure. 
Of the 26 compounds tested, the ent-kaurane family (compounds 1 – 7) isolated from 
Croton kongensis Gagnep. clearly exhibited the most interesting preliminary data and was 
therefore selected for further and more detailed pharmacological investigations. 
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1.2.2. Cytotoxicity effects of ent-kaurane diterpenoids on hepatocarcinoma cell lines 
As mentioned above, all the ent-kaurane compounds elicited a cytotoxic activity against 
both HepG2 and Hep3b cell lines without marked difference between the two cell lines. The 
fact that no significant difference was observed in the cytotoxic effect against HepG2 and 
Hep3b despite the distinct pharmacological properties of the two cell lines (Qiu G. H., 2015) 
suggested a cell line-independent mechanism of action of the compounds. Indeed, it is 
accepted that the cytotoxicity of ent-kaurane diterpenoids results from the formation of 
reactive oxygen species (ROS) through Michael reaction with regulatory thiol containing 
enzymes or coenzymes (Santagata S., 2012; Liu C. X., 2012; Lin Z., 2015), likely to be 
shared by the two HepG2 and Hep3b cell lines and others. 
The activity remained similar or weakly enhanced from 24 to 72 hours of incubation, 
with most of the IC50 values ranging from 3 to 10 µM. Cytotoxicity depended on the structure 
of the compound. Compound 5, for which the cytotoxic properties have not been tested in the 
literature, was the most active, with IC50 values around 3 µM, followed by compound 1. 
Cytotoxicity of compound 1 on HepG2 and Hep3b cell lines was in the same range as that 
measured on the SK-HEP1 cell line for the identical ent-kaurane diterpenoid named CrT1 (Sul 
Y. H., 2013). Activity of compounds 1, 2 and 4 against HCC HepG2 and Hep3b cell lines was 
comparable to the activity of identical molecules described against other tumor cell lines such 
as A549, MCF-7 or KB (Kuo P. C., 2007). Compounds 1, 2, 6 and 7 were also found active in 
the brine shrimp lethality assay (Phan M. G., 2005). 
Interestingly, all the compounds except compound 3, share the O=C–C=CH2 system, 
described to be responsible of the cytotoxicity of sesquiterpene antitumor agents (Lee K. H., 
1971; Lee K. H., 1977), and possess the 16-en-15-one basic skeleton shown to play an 
important role in the cytotoxic activity of ent-kaurane diterpenoids (Kuo P. C., 2007; Thuong 
P. T., 2014). Conversely, absence of a hydroxyl group at C7 position may contribute to a 
decreased activity (Kuo P. C., 2007). Consistent with this observation, compound 7, bearing 
the 16-en-15-one structure but lacking the hydroxyl group at the C7 position, exhibited, to a 
lesser extend, a decreased activity with IC50 values above 10 µM. Further, our observation 
correlates with the weak cytotoxic activity measured for compound 7 in the brine shrimp 
lethality assay (Phan M. G., 2005). Compound 3 which lacks both the 16-en-15-one basic 
skeleton and a hydroxyl group at C7 position, displayed the weakest activity, with IC50 values 
in the 100 µM range, i.e. 10 to 30 times higher than those of compound 5. Interestingly, it 
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must be noticed that the R5 methyl group which results in a well-known hyperconjugation 
effect (Figure 30), is only present in compound 3.  
 
 
Figure 30 : Structure with arrows illustrates the hyperconjugation effect for compound 3 
 
Hyperconjugation leads to a more stable structure and, consequently, to a less reactive 
functionality, which may affect the biological properties of ent-kaurane diterpenoids. In 
accord with our observation, an ent-kaurane diterpenoid identical to compound 3 showed no 
cytotoxicity in the brine shrimp lethality assay (Phan M. G., 2005) and was inactive in other 
biological assays such as inhibition of Silent information regulator two ortholog (SIRT1) 
(Dao T. T., 2010) or anti-staphylococcal activity (Giang P. M., 2006). 
 
1.2.3. Morphological changes induced by ent-kaurane diterpenoids on 
hepatocarcinoma cell lines 
Beside cytotoxicity assay, change in the morphology of the cell exposed to compounds 
may give pertinent information on the cellular processes underlaying cell death. As a part of 
morphological investigation, the modification in the cell shape was therefore observed under 
light microscope. Figure 31 describes the morphology of both HepG2 and Hep3b cell lines 
after 48 hours of incubation with an ent-kaurane diterpenoid. As shown, both of the two cell 
types got rounded and shrinked apart. 
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Figure 31 : Morphology of HepG2 (A) and Hep3b (B) hepatocarcinoma cell lines 
incubated (right panels) or not (left panels) with Vietnamese ent-kaurane diterpenoid 
compound 5 for 48 hours.  
 
To further explore the cellular mechanisms underlaying the observed cytotoxic effects, 
we used compound 5 as the representative molecule of our series of compounds. 
 
1.2.4. Concentration-dependent induction of subG1 phase by ent-kaurane 
diterpenoid compound 5 on human HCC HepG2 and Hep3b cell lines 
Cytometry analysis of the cell population in the SubG1 phase is commonly used to 
evaluate the pro-apoptotic properties of anti-tumor molecules. We tested compound 5 in a 
range of concentrations framing its IC50 values. Results are shown in Figure 32.  
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Figure 32 : Pro-apoptotic effect of ent-kaurane-type diterpenoid compound 5 on human 
hepatocarcinoma cell lines HepG2 and Hep3b. A – Hep G2 (upper panels) and Hep3b (lower 
panels) cells were incubated with no (control) or increasing concentrations (2 to 16 µM) of 
compound 5 for 48 hours followed by staining with propidium iodide. DNA content was 
analyzed by flow cytometry. Number of cells (Cell count) is represented as a function of 
DNA content (PI). The % of cells in subG1 is indicated. Data presented are from one 
representative experiment. B – Histograms showing the % of cells in subG1 phase as a 
function of increasing concentrations of compound 5. Columns and bars are the mean and SD 
from 3 independent experiments. 
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Panel A illustrates the cell population observed in absence or presence of increasing 
concentrations of compound 5 in representative experiments performed on HepG2 (upper 
panels) and Hep3b (lower panels) cell lines. Panel B shows that in absence of compound 5, 
the subpopulation of both HepG2 and Hep3b cell lines in the subG1 phase was low, around 
10% (11.2 ± 2.1 for HepG2 and 10.6 ± 6.9 for Hep3b). In presence of compound 5, the % of 
cells in the subG1 phase increased in a concentration-dependent manner, from around 30% 
(35.0 ± 13.3 for HepG2 and 27.5 ± 3.3 for Hep3b) at 2 µM of compound 5 to around 80% 
(80.3 ± 15.0 for HepG2 and 73.7 ± 11.1 for Hep3b) at 16 µM of compound 5. This 
observation evidenced the pro-apoptotic effect of compound 5. 
Although the difference was not statistically different, the % of subG1 population in 
presence of compound 5 was repeatedly and consistently higher for HepG2 than Hep3b at a 
given concentration of compound 5, suggesting a different sensitivity between the two cell 
lines. At the concentration of 4 µM, close to the IC50 values determined in the cytotoxicity 
assay at 48 hours (see Table 14), about half of the cell population was in the subG1 phase 
(56.0 ± 12.3 for HepG2 and 40.4 ± 9.7 for Hep3b). This is in favor of a correlation between 
the cytotoxic and pro-apoptotic properties of compound 5. Interestingly, the % of subG1 
population of HepG2 and Hep3b cell lines induced by compound 5 in our study are quite 
comparable to those obtained with CrT1(identical to compound 1) on the SK-HEP1 cell line 
(Sul Y. H., 2013). 
These findings, observed on three different HCC cell lines, suggest that ent-kaurane 
diterpenoids might share common or closely related pro-apoptotic mechanisms of action 
leading to apoptosis in human HCC cell lines. 
 
1.2.5. Concentration-dependent induction of apoptosis by ent-kaurane diterpenoid 
compound 5 on human HCC HepG2 and Hep3b cell lines 
Concomittent analysis of annexin V and propidium iodide by flow cytometry allowed the 
identification of early and late apoptotic stages and therefore brought a more detailed insight 
on ent-kaurane diterpenoid-induced apoptosis. Results are presented in Figure 33. 
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Figure 33 : Induction of apoptosis of human hepatocarcinoma cell lines HepG2 and 
Hep3b by ent-kaurane-type diterpenoid compound 5. HepG2 and Hep3b cells were incubated 
with no (control) or increasing concentrations (2 to 16 µM) of compound 5 for 48 hours 
followed by staining with Annexin V FITC and propidium iodide. DNA content and Annexin 
V expression were analyzed by flow cytometry. A and B - Data presented are from one 
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representative experiment performed on HepG2 (A) and Hep3b (B) cell lines. In the upper left 
panel, the light scattered properties of control cells (FSC-A, SSC-A) are shown. In each other 
panel, viable, early apoptotic and late apoptotic cells are gated in lower left, lower right and 
upper right quarters respectively (debris are shown in upper left quarter). C and D – 
Percentage (%) of viable, early apoptotic and late apoptotic (black, white and grey columns 
respectively) HepG2 (C) and Hep3b (D) cells as a function of increasing concentrations of 
compound 5. Columns and bars are the mean and SD from 3 independent experiments. 
 
Panel A illustrates the observed cell population in absence or presence of increasing 
concentrations of compound 5 in a representative experiment performed on HepG2 cell line. 
A similar pattern was obtained with the Hep3b cell line (Panel B). As shown in panels C 
(HepG2) and D (Hep3b), a high proportion (%) of cells was viable and non-apoptotic (73.8 ± 
2.1 for HepG2 and 79.4 ± 8.3 for Hep3b) in absence of compound 5. 
When incubated with compound 5, the % of viable cells declined in a concentration-
dependent manner. In good agreement with the IC50 values determined in the cytotoxicity 
assay and the observations made in subG1 experiments, the population of viable cells at 4 µM 
was slightly below 50% (37.9 ± 4.1 for HepG2 and 43.5 ± 17.7 for Hep3b). This further 
supported the link between the cytotoxic and apoptotic properties of compound 5. At the 
highest concentration tested, viability of HepG2 cells was dramatically affected (4.1 ± 3.5) 
whereas that of Hep3b cells remained rather stable (19.3 ± 4.1), suggesting, as noted before, a 
different sensitivity of the two cell lines. In parallel, there was an increase in early apoptotic 
cell populations which reached a plateau around 40% for both cell lines at the highest 
concentration of compound 5 (34.7 ± 7.2 for HepG2 and 38.9 ± 14.7 for Hep3b). The double 
positive cell population (which contains late apoptotic and/or necrotic cells) also increased 
with a marked difference between the two cell lines, increase being continuous for HepG2 
(60.6 ± 3.5) but stabilized around 40% for Hep3b (41.4 ± 11.9) at 16 µM of compound 5. In 
HepG2 cells, the high % of late apoptotic cells correlated with the low % of viable cells. In 
striking contrast with our observation, late apoptosis was barely detectable in HepG2 cells 
incubated with longikaurin A, a natural ent-kaurane (Liao Y. J., 2014). 
Two additional and complementary observations sustained evidence of apoptosis in both 
HepG2 and Hep3b cell lines. First, under light microscope, we observed rounded and 
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shrinked cells upon exposure of both cell lines to compound 5. Second, in correlation with 
these morphological changes, cells showed altered flow cytometry light scatter properties, 
Figure 34 illustrates a decrease in forward scatter (FSC-A, X axis) and an increase in side 
scatter (SSC-A, Y axis), which resulted from cell shrinking and apoptotic vesicles formation 
respectively for HepG2 (Panel A) and Hep3b (Panel B). 
 
 
Figure 34 : Flow cytometry light scatter properties of human hepatocarcinoma cell lines 
HepG2 and Hep3b incubated with ent-kaurane-type diterpenoid compound 5. HepG2 and 
Hep3b cells were incubated with no (control) or increasing concentrations (2 to 16 µM) of 
compound 5 for 48 hours followed by staining with Annexin V FITC and propidium iodide. 
Data presented the light scattered properties (FSC-A, SSC-A) from one representative 
experiment performed on HepG2 (Panel A) and Hep 3b (Panel B) cell lines. 
 
The cellular components involved in apoptosis of HepG2 and Hep3b cells lines induced 
by compound 5 remain to be identified. Along this line, two different, but not exclusive, 
apotototic cellular pathways triggered by ent-kaurane diterpenoids in two different HCC cells 
have been reported recently: the regulation of AMP-activated protein kinase by CrT1, isolated 
from Croton kongensis in SK-Hep1 cells (Sul Y. H., 2013), and the activation of ROS/JNK/c-
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Jun pathway by longikaurin A, isolated from Isodon ternifolius, in SMMC-7721 cells (Liao 
Y. J., 2014). 
 
1.2.6. Ent-kaurane diterpenoids potentiate the cytotoxic activity of doxorubicin on 
human HCC cell lines 
1.2.6.1. Sub-toxic concentration of ent-kaurane diterpenoids enhances the cytotoxicity of 
doxorubicin in human HCC HepG2 and Hep3b cell lines 
Doxorubicin is one of the most commonly used chemotherapeutic agent against various 
cancers including HCC (Weiss R. B., 1992; Tam K., 2013). However, as a single agent, 
efficacy of doxorubicin against HCC remains limited, mainly due to chemoresistance and 
severse side effects (Carvalho C., 2009). Combined therapy has emerged as a strategy for 
improving the therapeutic effects of doxorubicin in HCC (Cervello M., 2012; Finn R. S., 
2013). In this field, few natural molecules have been successfully used to enhance the 
cytotoxic effect of doxorubicin in ovarian (Fong M. Y., 2012) or liver (Lee W. Y.,2010; Fan 
C., 2014; Gambari R., 2013) cancer cells. In the framework of further researches on ent-
kaurane diterpenoids, compound 1 to 7 were used to study whether they can potentiate the 
cytotoxic effects of doxorubicin on human HCC HepG2 and Hep3b cell lines.  
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  Cytotoxic activity (%) 
  HepG2  Hep3b 
doxo alone  9.3  ± 6.3 -  8.5  ± 4.5 - 
doxo + cpd 1  38.5  ± 3.7 (0.3  ± 5.5)  81.8  ± 7.4 (1.7  ± 1.2) 
doxo  + cpd 2  37.3  ± 5.3 (2.3 ± 2.1)  63.0  ± 11.2 (0.3 ± 2.3) 
doxo  + cpd 3  24.3  ± 2.5 (2.3 ± 4.0)  55.5  ± 14.3 (0.3 ± 1.5) 
doxo  + cpd 4  39.5  ± 3.9 (3.0  ± 4.6)  72.8  ± 11.3 (1.3  ± 3.8) 
doxo  + cpd 5  49.8  ± 2.1 (2.0  ± 4.4)  79.0  ± 10.1 (2.0  ± 3.6) 
doxo  + cpd 6  39.3  ± 6.0 (4.0  ± 3.6)  59.0  ± 3.4 (2.7  ± 1.2) 
doxo  + cpd 7  25.5  ± 7.0 (2.7  ± 5.5)  42.5  ± 6.5 (2.0  ± 2.6) 
Table 15 : Cytotoxic activity (%) of doxorubicin alone or in presence of ent-kaurane 
diterpenoids (compounds 1 to 7) on human HepG2 and Hep3b hepatocarcinoma cell lines 
after 24 hours of incubation. Results are expressed as the mean ± SD values from three 
independent experiments. Doxorubicin (Dox) was used at 4 µM. Compounds (cpd) 1 to 7 
were used at subtoxic concentrations (i.e. inducing less than 5 % cytotoxicity). Activity of 
compounds 1 to 7 alone are shown in parentheses. 
 
As shown in Table 15, doxorubicin at a concentration of 4 µM displayed a weak 
cytotoxicity (9,3 ± 6.3 % for HepG2 and 8.5 ± 4.5 % for Hep3b cell lines) when used alone. 
When ent-kaurane diterpenoids were added at sub-toxic contentrations (less than 5% 
cytotoxicity), a dramatic potentiation effect was observed in both HepG2 and Hep3b cell lines 
Whatever the compound, sensitivity to doxorubicin was much higher for Hep3b than HepG2 
cell lines. For example: with compound 1, the percentage of cell death was 38.5 ± 3.7 % for 
HepG2 and 81.8 ± 7.4 % for Hep3b. 
Since no significant difference was observed between the seven compounds, compound 5 
was chosen as the representative compound for a further detailed investigation to clarify the 
mechanism of potentiation induced by ent-kaurane diterpenoids. 
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1.2.6.2 Sub-toxic concentration of ent-kaurane compound 5 strongly enhances the 
cytotoxicity of doxorubicin in human HCC cell lines 
As shown in Table 16 and Figure 35, a low, subtoxic concentration of compound 5 
efficiently sensitized both HepG2 and Hep3b cell lines to doxorubicin cytotoxicity in a time-
dependent manner. Cytotoxicity of doxorubicin alone increased regularly with IC50 values 
ranging from 109.3 ± 7.7 µM to 26.5 ± 1.8 µM for HepG2 and from 86.9 ± 7.3 µM to 25.1 ± 
2.1 µM for Hep3b between 6 hours and 48 hours of incubation. 
 
Incubation 
time (hrs) 
 IC50 (µM) 
 HepG2  Hep3b 
 Dox Dox + cpd 5  Dox Dox + cpd 5 
6  109.3 ± 7.7 79.4 ± 6.0 (1.4)  86.9 ± 7.3 64.5 ± 3.8 (1.3) 
12  66.6 ± 13.4 9.2 ± 0.9 (7.9)  56.2 ± 3.0 6.2 ± 0.5 (9.1) 
24  50.8 ± 3.3 4.8 ± 0.6 (11)  49.3 ± 17.3 5.1 ± 0.3 (9.7) 
48  26.5 ± 1.8 3.2 ± 0.6 (8.3)  25.1 ± 2.1 2.3 ± 0.3 (11) 
Table 16 : Cytotoxic activity (IC50, µM) of doxorubicin (Dox) in absence or in presence 
of ent-kaurane diterpenoid compound 5 (cpd 5) on human HepG2 and Hep3b hepatocellular 
carcinoma cell lines after 6, 12, 24 and 48 hours of incubation. Results are expressed as the 
mean ± SD values from three independent experiments. For a given time, the ratio of the IC50 
values of doxorubicin in absence / in presence of compound 5 is shown in parentheses. 
 
As shown in Figure 35 from 12 to 48 hours, compound 5 dramatically enhanced the 
cytotoxicity of 20 µM doxorubicin, cell viability decreasing to less than 5% at 48 hours 
(compared to 60 % for doxorubicin alone). Accordingly, a significant - 8 to 11 fold – decrease 
was measured for the IC50 values (Table 16). Conversely however, at 6 hours of incubation, 
compound 5 had only a weak to moderate effect on the IC50 values (IC50 ratio < 2, Table 16) 
and did not enhance the cytotoxic effect of 20 µM doxorubicin (Figure 35) in both cell lines. 
This 6 hour-delay ruled out the hypothesis of an immediate, non-specific action of compound 
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5, such as disruption of the cellular membrane integrity, which would allow doxorubicin to 
better penetrate the cell. It indicated that the sensitization effect of compound 5 necessitated 
triggering of intracellular pathways, which remain to be characterized. 
 
 
Figure 35 : Sensitization of human hepatocarcinoma cell lines HepG2 and Hep3b to 
doxorubicin cytotoxicity by ent-kaurane-type diterpenoid compound 5. Cell viability was 
analyzed as a function of time and measured using a MTT assay. HepG2 (left panel) and 
Hep3b (right panel) cells were incubated during 6, 12, 24 or 48 hours with 20 µM doxorubicin 
alone (full circle) or in combination to compound 5 at a subtoxic concentration (1 µM, full 
square) of compound 5. As control, compound 5 alone at 1 µM (open triangle) exhibited no 
significant cytotoxicity. Values shown are the mean ± SD from three independent 
experiments. For a given time, p value < 0.05 (*) or < 0.001 (***) indicated statistically 
significant differences between measures done with doxorubicin alone and in combination to 
compound 5. 
 
Enhanced ROS production has been associated to the cumulative effects between 
doxorubicin and withaferin A in ovarian cancer (Fong M. Y., 2012) or selenocystine in HCC 
(Fan C., 2014). Interestingly, as discussed above, ent-kaurane diterpenoid-induced formation 
of ROS also mediates cytotoxicity (Lin Z., 2015) and apoptosis (Thuong P. T., 2014). The 
fact that ROS generation is also one of the mechanisms of action involved in doxorubicin 
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antitumor activity (Gewirtz DA., 1999; Minotti G., 2004) may be a possible explanation of 
the observed additive effects between compound 5 and doxorubicin. To complete our work, 
further biochemical studies are necessary to confirm this hypothesis. All together, these data 
suggest that ent-kaurane diterpenoid-induced ROS formation may play a dual role in cancer 
cells: sensitization at low subtoxic concentrations on one hand, apoptosis-mediated 
cytotoxicity at higher concentrations on the other. 
 
2. Virtual Screening research and Biochemical studies of 
solasonine 
2.1. Results of Virtual Screening database of Vietnamese plants 
2.1.1. In silico screening of natural products library isolated from Vietnamese plants 
The 354 molecules were screened for their ability to interact both with mortalin on one 
side and p53 on the other using the models 3N8E and 1AIE for mortalin and p53 respectively. 
As shown in Figure 36, most of the molecules exhibited a moderate or weak binding 
score. A set of 11 molecules out of 354 (3.1 %) with a high binding score emerged, among 
which a subset of 5 with values higher than 200 (Table 17). 
With the lowest binding energy of mortalin interaction (-15.62 kcal/mol) and the fourth 
lowest binding energy of p53 interaction (-14.53 kcal/mol), solasonine, a steroidal alkaloid 
glycoside (Figure 37) isolated from the Vietnamese plant Solanum xanthocarpum displayed 
the highest combined score. Very interestingly, solamargine, a closely related molecule, 
exhibited the fourth highest combined score. 
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Figure 36 : Binding score of the 354 natural compounds from the Vietnamese plants 
database. For a given compound, the binding score was defined as the product of its 
respective binding energies to mortalin and p53. The insert shows the 2D distribution (p53 vs 
mortalin) of the binding energies of the 354 compounds (1 dot represents 1 compound). The 5 
compounds with the highest binding scores (values > 200) are circled in the insert. 
 
 
                                                R = solatriose 
Figure 37 : solasonine structure 
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Rank Compound Binding score 
Binding energy 
(kcal/mol) 
Mortalin p53 
1 solasonine 226,96 - 15,62 - 14,53 
2 acantrifoside C 220,27 - 14,12 - 15,60 
3 acantrifoside B 212,08 - 13,56 - 15,64 
4 solamargine 207,50 - 14,42 - 14,39 
5 
quercetin-3,7-dimetylether-
3'-O--L-rhamnopyranosyl-
(1→2)--D-glucopyranosid 
202,00 - 13,53 - 14,93 
 withanone (control) 106.29 - 10.40 - 10.20 
Table 17 : The five natural compounds with the highest binding score. The binding score 
(middle column) was defined as the product of the binding energies to mortalin and p53 (two 
right colums). Withanone is shown as a control. 
 
Solamargine and solasonine have been described to exert antiproliferative activity in 
different tumor cell lines (Munari C. C., 2014). Further, solamargine has been shown to 
trigger apoptosis in human Hep3b (Kuo K. W., 2000), SMMC-7721 and HepG2 (Ding X., 
2012; Xie X., 2015) hepatoma or osteosarcoma U2OS (Li X., 2011) cell lines. Withanone, a 
withanolide isolated from Withania somnifera, shown to bind to mortalin and to abrogate 
mortalin – p53 interactions (Grover A., 2012; Vaishnavi K., 2012) was screened as a control. 
In our assay, withanone was ranked at the 34th position, interacting with mortalin (PDB-ID: 
3N8E) with a binding energy (-10.4 kcal/mol) comparable to that previously described using 
the same model (Vaishnavi K., 2012).  
In additional experiments, we measured the binding energy of solasonine, solamargine 
and withanone in two other structural models 4KBO and 3D09 of mortalin and p53 
respectively: model 4KBO focuses on domain aa 253-282 of mortalin also described as a 
possible site of interaction with p53 (Grover A., 2012) and p53 model 3D09 representing the 
p53 sequence aa 96-290 which is suggested to affect its interaction with mortalin (Vaishnavi 
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K., 2012). In these two models, solasonine and withanone showed the lowest and highest 
binding energy respectively (Table 18). 
 
Compound 
Mortalin p53 
3N8E 4KBO 1AIE 3D09 
solasonine - 15.62 - 9.63 - 14.53 - 14.14 
solamargine - 14.42 - 9.15 - 14.39 - 13.63 
withanone - 10.40 - 7.11 - 10.22 - 8.36 
Table 18 : Binding energies of solasonine and solamargine to mortalin and p53. Binding 
energy (kcal/mol) was calculated in two differents models of mortalin (3N8E and 4KBO) and 
in two differents models of p53 (1AIE and 3D09). Withanone was used as the control. 
 
Also, all the three compounds bound with a better binding energy to aa 439-597 sequence 
(model 3N8E) than to aa 253-282 sequence (model 4KBO) of mortalin and with a better 
binding energy to aa 312-352 sequence (model 1AIE) than to aa 96-290 sequence of p53. One 
can thus hypothesize that the preferential binding sites of these compounds on either mortalin 
and/or p53 will be those of respective lowest binding energy. 
 
2.1.2. Docking of solasonine into mortalin and p53 
Solasonine was then docked into mortalin and p53 using the models 3N8E and 1AIE 
respectively, for which solasonine presented the better interactions. Docking is illustrated in 
Figure 38 and hydrogen bond interactions are reported in Table 19.  
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Figure 38 : Interactions of docked solasonine with mortalin (left panels) and p53 (right 
panels). A - Solasonine occupying the mortalin and p53 spaces that are crucial for their 
interaction. Nitrogen, oxygen and aliphatic carbon atoms of the proteins are colored in blue, 
red and grey respectively. B - Multi-template homology modeled 3D structures. C - Closer 
views showing the hydrogen bonds between solasonine and mortalin or p53. The interacting 
residues of mortalin or p53 are shown in yellow. 
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Protein Hydrogen bond interactions Distance (Å) Binding energy (kcal/mol) 
Mortalin 
(3N8E) 
Ala (475) O … H 1.935 
- 15.62 
Gln (479) OE1 … H 1.961 
Arg (513) HE … O 1.966 
Glu (577) OE2 … H 1.767 
p53 
(1AIE) 
Glu (326) HN2 … O 2.176 
- 14.53 Phe (328) HN … O 1.875 
Leu (330) O … H 2.061 
Table 19 : Hydrogen bond interactions between solasonine and mortalin or p53. The 
protein models used are 3N8E for mortalin and 1AIE for p53. The residues involved in an 
hydrogen bond with solasonine are mentioned and their interacting atoms are underlined. 
Calculated distance (Å) is indicated for each hydrogen bond. The binding energy (kcal/mol) 
of solasonine to each protein is recalled. 
 
As shown, solasonine bound efficiently to mortalin with a low binding energy (-15.62 
kcal/mol) by forming strong hydrogen bonds (with distances shorter than 2 Å) with 4 residues 
(Ala 475, Gln 479, Arg 513 and Glu 577) located in the substrate binding domain of mortalin. 
Interestingly, one of these residues, Arg 513, has been described as the “latch” between the 
“lid and cleft regions” of mortalin, thereby playing an important role in the chaperone 
function of this protein (Kaul S. C., 2007). Withanone and the related withanolide molecule 
withaferin-A have also been shown to interact with Mortalin Arg 513 (Vaishnavi K, 2012). 
Solasonine also bound to p53 but less efficiently than to mortalin both in terms of binding 
energy (- 14.53 kcal/mol) and affinity by engaging only 3 hydrogen bonds formed with 3 
residues (Glu 326, Phe 328 and Leu 330). On the basis of these interactions with residues 
located within the “hot spot” of mortalin – p53 interactions, one may thus hypothesize that 
solasonine will behave as a potent inhibitor of these interactions by binding with high affinity 
to mortalin and/or, to a lesser extend, p53. 
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2.2. Pharmacological studies of solasonine in HepG2 and Hep3b cell 
lines 
2.2.1. Cytotoxic activity of solasonine in HepG2 and Hep3b cell lines 
The inhibitory effects of solasonine on HepG2 and Hep3b cell viability was first 
measured at 24 hours and 48 hours of incubation and compared with those of solamargine and 
withanone (Table 20). 
 
 IC50 (µM) 
 24hrs 48 hrs 
 HepG2 Hep3b HepG2 Hep3b 
solasonine 7.1 ± 0.4 4.5 ± 0.3 4.7 ± 0.2 4.0 ± 0.1 
solamargine 7.6 ± 0.4 3.9 ± 0.1 5.5 ± 0.5 3.8 ± 0.2 
withanone 12.3 ± 1.4 8.2 ± 0.4 5.1 ± 0.3 4.4 ± 0.1 
Table 20 : Cytotoxic activity of solasonine and solamargine in HepG2 and Hep3b cell 
lines. IC50 (µM) were measured at 24 and 48 hours of incubation in presence of increasing 
concentrations of solasonine (0.032 - 500 µM) in HepG2 and Hep3b cell lines. Withanone 
was used as a positive control. Data are the mean ± SD of three independent experiments. 
 
For each time and in each cell line, solasonine and solamargine exhibited a similar 
activity. At 24 hours, solasonine and solamargine showed higher IC50 values in HepG2 (7.1 ± 
0.3 µM and 7.6 ± 0.4 µM respectively) than in Hep3b (4.5 ± 0.3 µM and 3.9 ± 0.1 µM 
respectively). At 48 hours, the IC50 values observed were lowered in HepG2 (4.7 ± 0.2 µM 
and 5.5 ± 0.5 µM respectively), being closer and comparable to those observed in Hep3b, 
which remained unchanged (4.0 ± 0.1 µM and 3.9 ± 0.2 µM respectively). In a second time, 
the antiproliferative activity of solasonine was measured as a function of time (Figure 39). 
HepG2 cells were less sensitive than Hep3b cells to solasonine. As shown in Figure 39 A, in 
presence of 20 µM solasonine, HepG2 cell viability decreased in a time-dependent manner, 
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reaching 50% after 6 hours and remaining stable around 20% after 24 hours. In contrast to the 
observation made in HepG2, Hep3b cell viability decreased dramatically within the first 1.5 
hour, reaching around 25% after 3 hours and being less than 5% after 12 hours. 
 
 
Figure 39 : Cytotoxic activity of solasonine in HepG2 and Hep3b cell lines. A – Cell 
viability was measured as a function of time of incubation in presence of solasonine (20 µM) 
in HepG2 (black circles) and Hep3b (white circles) cell lines. B – IC50 (µM) were measured 
as a function of time of incubation in presence of increasing concentrations of solasonine 
(0.032 - 500 µM) in HepG2 (black histogram) and Hep3b (white histogram) cell lines. In A 
and B, data are the mean ± SD of three independent experiments. 
 
This latest finding was similar to that observed previously with solamargine in the same 
Hep3b cell line (Kuo K. W., 2000). Further experiments done in presence of increasing 
concentrations of solasonine allowed the measurement of IC50 values as a function of time 
(Figure 39 B). The IC50 values at 24 hours and 48 hours have been reported above (see Table 
20). For shorter times, a marked difference was observed between the two cell lines. From 12 
hours to 1.5 hour, the IC50 values increased gradually in HepG2 (from 18.4 ± 0.9 µM to 38.0 
± 8.2 µM) whereas they remained stable in Hep3b in the 10 µM range (from 8.1 ± 0.2 µM to 
10.5 ± 1.0 µM). 
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Analyzing the molecular or cellular parameters explaining such a difference in the 
cytotoxic activity in the two cell lines at short incubation times (below 12 hours) falls out of 
the scope of the present work but remains to be explored in further studies. However, one 
possible explanation could come from the morphology and membrane structure which differ 
between the two cell lines, the thinner cellular membrane of the Hep3b cells allowing a rapid 
penetration of solasonine within the cell and thus increasing its cytotoxicity.  
 
2.2.2. Effect of p53 inhibitor pifithrin-alpha (PFT-α) on solasonine-induced 
cytotoxicity 
Cytotoxic properties of solasonine were further tested in absence or presence of PFT-α, a 
small molecule inhibitor of p53 function (Komarov P. G., 1999). Solasonine was used at 
concentrations around the IC50 values determined previously at 12 hours and 24 hours of 
incubation. As shown in Figure 40, PFT-α restored viability of HepG2 cells in a 
concentration-dependent manner at both time of incubation. 
At 12 hours, the effect was statistically significant with a marked increased in cell 
viability, from 53.9 ± 3.1 % in absence of PFT-α to 83.6 ± 7.2 % in presence of 30 µM PFT-
α. The same significant effect, but less marked, was also observed at 24h, cell viability 
increasing from 51.4 ± 1.6 % in absence of PFT-α to 67.4 ± 0.7 % in presence of 30 µM PFT-
α. In the same conditions, viability of Hep3b cell was unaffected by exposure to PFT-α (from 
55.7 ± 4.7 % in absence of PFT-α to 57.3 ± 0.7 % in presence of 30 µM PFT-α at 12 hours 
and from 51.9 ± 4.1 % in absence of PFT-α to 52.8 ± 1.6 % in presence of 30 µM PFT-α at 24 
hours). 
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Figure 40 : Effect of PFT-α on solasonine-induced cytotoxicity. Viability of HepG2 and 
Hep3b cells was measured after 12 hours (left panel) and 24 hours (right panel) of incubation 
in presence of solasonine at a concentration close to its respective IC50 values for each cell 
line (see figure 39 B), in absence (white histograms) or presence of 10, 20 or 30 µM of PFT-α 
(light grey, grey and black histograms respectively). Histograms and bars are the means ± SD 
of three independent experiments. 
 
At 12 hours, an almost complete reversion of cell viability could be obtained by blocking 
p53 function.  However, PFT-α has been reported to mediated this effect regardless of the 
presence or absence of p53 (Sohn D., 2009). In our hands, effect of PFT-α on cell viability 
was clearly and only observed in p53 expressing HepG2 and not at all in the p53 deficient 
Hep3b cell line. This suggests that the cytotoxic effect of solasonine may be either p53-
dependent and/or p53-independent in these two hepatoma cell lines. 
 
2.2.3. Apoptotic properties of solasonine in HepG2 and Hep3b cell lines 
For each cell line, the concentrations of solasonine were chosen around the respective 
IC50 values determined at 24 hours in the cytotoxicity assay (i.e. 7.1 ± 0.3 µM for HepG2 and 
4.5 ± 0.3 µM for Hep3b, see Table 20 above). Results are presented in Figure 41. 
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Figure 41 : Induction of apoptosis of human hepatocarcinoma cell lines HepG2 and 
Hep3b by solasonine. HepG2 and Hep3b cells were incubated with no (control) or increasing 
concentrations of solasonine for 24 hours followed by staining with Annexin V FITC and 
propidium iodide. DNA content and Annexin V expression were analyzed by flow cytometry. 
A - Data presented are from one representative experiment performed on HepG2 and Hep3b 
cell lines. In each panel, viable, early apoptotic and late apoptotic cells are gated in lower left, 
lower right and upper right quarters respectively (debris are shown in upper left quarter). B – 
Percentage (%) of viable, early apoptotic and late apoptotic (white, grey and black circles 
respectively) HepG2 and Hep3b cells as a function of increasing concentrations of solasonine. 
Data are the mean and SD from 3 independent experiments. 
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Panel A illustrates the observed cell populations in absence or presence of increasing 
concentrations of solasonine in a representative experiment performed on HepG2 or Hep3b 
cell lines. As shown in panel B, when both cell lines were incubated for 24 hours with 
solasonine, the % of viable cells declined in a concentration-dependent manner, dropping 
from about 70% in absence of solasonine to about 20% at the highest concentration of 
solasonine tested. In parallel, the number of cells in the double positive cell populations 
(which contain late apoptotic and/or necrotic cells) increased in a continuous manner for 
HepG2 and Hep3b cell lines from about 10% in absence of solasonine to about 50-60 % at the 
highest concentration of solasonine tested. In contrast, the % of early apoptotic cell 
populations was rather stable and remained below 15-20% even at the highest concentration 
of solasonine tested.  
 
2.2.4. Subcellular localization of p53 upon exposure to solasonine in HepG2 cell line 
As a first control experiment, we analyzed the presence of p53 and mortalin in each HCC 
cell line. As shown in Figure 42 A, mortalin was present in both HepG2 and Hep3b cell lines, 
as previously reported (Xin Y., 2008; Chen J., 2014). In contrast, as expected, p53 was 
present only in HepG2 cell line and not detectable in Hep3b cell line, as previously reported 
(Lu W. J., 2011).  
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Figure 42 : A – Western-blot detection of mortalin and p53 in HepG2 and Hep3b cell 
lines. Beta actin was used as the loading control. Results are expressed as the ratio between 
band intensity of mortalin and beta actin (black and white histograms, left figure) or p53 and 
beta actin (black and white histograms, right figure). B - Western-blot detection of p53 and 
p21 in cytoplasmic, soluble nuclear and insoluble nuclear fractions of HepG2 and Hep3b cell 
lines in absence or presence of increasing concentrations of solasonine. Beta actin was used as 
the loading control in cytoplasmic fractions. Cleaved PARP and cleaved Lamin B1 were used 
as apoptosis markers in soluble nuclear and insoluble nuclear fractions respectively. C- p53 
band intensity measured as a function of solasonine concentration in the cytoplasmic, soluble 
nuclear and insoluble nuclear fractions (white, black and grey histograms respectively). For 
each fraction, band intensity in absence of solasonine was used as the reference value (100).  
D – p53 band intensity ratio measured between soluble nuclear and cytoplasmic fractions 
(black circles) and between insoluble nuclear and cytoplasmic fractions (grey circles) as a 
function of solasonine concentration. The ratio measured in absence of solasonine was used as 
the reference ratio (= 1). In panels A, C and D, data are the mean ± SD of 3 independent 
experiments. 
 
Subcellular localization of p53 in HepG2 cells was then analyzed in absence or presence 
increasing concentrations of solasonine (Figure 42 B, C). In absence of solasonine, p53 was 
present mainly in the cytoplasmic fraction and, to a lesser extend, in the soluble nuclear 
fraction, while being barely detectable in the insoluble nuclear fraction. 
In presence of solasonine, the amount of p53 increased in a concentration-dependent 
manner in all the three fractions (Figure 42 B, C). The increased amount of p53 was more 
important in the nucleus (both soluble and insoluble fractions) than in the cytoplasm (Figure 
42 C, D), reflecting or resulting of a translocation of p53 from cytoplasmic to the nucleus. 
One can reasonably hypothesize that this is the consequence of the inhibition of p53 - 
mortalin interaction by solasonine and the abrogation of the cytoplasmic sequestration of p53 
by mortalin. 
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2.2.5. Activation of signaling pathways upon exposure to solasonine in HepG2 and 
Hep3b cell lines 
Accumulation of p53 protein in the nucleus leads to the activation of numerous target 
genes that mediate its tumor suppressor functions, among which p21Waf1/Cip1, a member of 
the Cip/Kip family of cyclin-dependent kinase inhibitors (Harris S. L., 2005). In addition to 
its cell-cycle inhibitor function, p21 has been reported to affect, either negatively or 
positively, p53 induction of apoptosis (Abbas T., 2009). As shown in Figure 42 B, in 
unexposed HepG2 cells, as expected, p21 was absent (cytosolic and insoluble nuclear 
fractions) or barely detectable (soluble nuclear fraction). In HepG2 cells exposed to 
solasonine, concomitant with p53 accumulation in the nucleus, p21 expression also increased 
in a concentration-dependent manner, predominantly in the soluble nuclear fraction. The role 
played by p21 in HepG2 cells incubated by solasonine remains to be defined in further 
studies. In p53 negative Hep3b cells, no p21 expression was observed neither in the 
cytoplasmic nor the nuclear fractions, as expected. 
To further assess the apoptotic properties of solasonine, we analyzed the ability of 
solasonine to induce the cleavage of nuclear lamin B1 and poly (ADP-ribose) polymerase 
PARP proteins. Cleavage products resulting from the enzymatic action of caspase on these 
two proteins represent markers for apoptosis. As shown in Figure 42 B, incubation of HepG2 
cells with increasing amount of solasonine resulted in a concentration-dependent formation of 
cleaved PARP and cleaved Lamin B1 as detected in the soluble and insoluble nuclear 
fractions respectively. Interestingly, these two cleaved products were also observed in nuclear 
fractions of Hep3b cells. 
This observation indicated that solasonine does induce apoptosis in both p53-expressing 
and p53-deficient cell lines, in accordance with the observations made in the annexin V – PI 
experiments (Figure 41) discussed above via p53-dependent in HepG2 cells and p53-
independent mechanism in Hep3b cells. In these later ones, the mechanism by which 
solasonine induces apoptosis remains to be elucidated. Since mortalin is present in Hep3b 
cells (Figure 42 A, Xin Y., 2008; Chen J., 2014), a possible hypothesis is that solasonine is 
also able to inhibit the interaction between mortalin, and a transcription factor implicated in 
p53-independent apoptosis pathways, then allowing it to translocate to the nucleus. Further 
studies are needed to confirm this hypothesis. 
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Until now, despite all the efforts made in the search for effective treatments of 
hepatocellular carcinoma, none of the approaches have been satisfactory and have not yet 
resulted in highly efficient treatments. Therefore, the objective of finding new bioactive 
compounds and/or new therapeutic strategies must not be abandoned. Keeping this in mind, 
two approaches have been followed in this thesis focused on the study of Vietnamese natural 
compounds originated from plants.  
The first part of this thesis was focused on the pharmacological screening of a database of 
26 natural compounds. As a results, 7 diterpenoids (the ent-kaurane family) were identified to 
be potential bioactive against hepatocarcinoma, through a classical cytotoxicity assay. The 
mechanism of action of these compounds has been then explored in deeper details.  
Our study not only showed that ent-kaurane diterpenoids displayed a structure-related, 
concentration-dependent, apoptosis-induced cytotoxicity against two human HCC model cell 
lines but also revealed that they were active at sub-toxic concentration, by sensitizing HCC 
cells to the anticancer agent doxorubicin. As previously proposed for other natural products 
(Lee W. Y., 2010; Fong M. Y., 2012; Fan C., 2014; Gambari R., 2014), interaction of ent-
kaurane diterpenoids with doxorubicin may be viewed as a possible way to enhance the 
antitumor therapeutic effects of doxorubicin. Conversely, ROS accumulation is involved in 
the cardiotoxic side effects of doxorubicin (Minotti G., 2004; Hequet O., 2014) and 
cumulative ROS generation could then result in an unwished potentiation of cardiotoxicity. 
Taken all together, our data bring strong support to the potential interest of ent-kaurane 
diterpenoids in the cancer field and more precisely against HCC. Eventhough virtually no 
acute toxicity has been observed in vivo (Zou Q. F., 2013), the side effects of ent-kaurane 
diterpenoids remain poorly documented to date and their careful evaluation should be 
undertaken, in a perspective of future clinical applicability and development (Wang L., 2011). 
In parallel, one may expect that the intrinsic low aqueous solubility and weak bioavailability 
of these natural products (Xu W., 2006) could be successfully overcome through, for 
example, ent-kaurane-based design of synthetic molecules (Ding C., 2014). 
In the second approach, 354 compounds originated from Vietnamese plants were 
virtually screened using AutoDock program in an effort to find appropriate molecules that can 
abrogate the interaction between Mortalin and p53. So doing, solasonine was identified as the 
most potential compound. Pharmacological studies demonstrated that solasonine inhibited 
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Mortalin – p53 interaction, allowing p53 to translocate from cytoplasm into nucleus and then 
inducing cell death of human hepatocellular carcinoma cell lines through a p53-dependent 
pathways. Solasonine can exert its action by interacting with high affinity to either mortalin or 
p53. Interestingly enough, one may note that none of the numerous and critical mutations 
affecting p53 in cancer cells (Tornesello M. L. 2013; http://www-p53.iarc.fr) lies in the p53 
sequence to which binds solasonine. With no doubt, this represents an added value to the 
original pharmacologic properties of solasonine. In parallel to its p53-dependent apoptotic 
properties in p53-expressing hepatoma cells, we also evidenced powerful p53-independent 
apoptotic effects of solasonine in p53-deficient hepatoma cells. Eventhough this mechanism 
remains to be fully elucidated, this dual and complementary properties may bring a further 
additional interest to solasonine by making wider the panel of cancer cells sensitive to 
solasonine. Additional studies must be undertaken to support the preliminary results obtained 
in this thesis. In particular, the interactions between mortalin and p53 should be analyzed at 
the molecular and biochemical levels on purified proteins or cell extracts and at the biological 
level by using immunostaining and microscope analysis. 
In terms of perspective, two complementary axis of research can logically be proposed. 
First, on the “pharmacological side”, more studies are, indeed, needed to validate as 
“promising leads” the natural compounds identified in this study. In particular, if we keep in 
mind the ultimate goal of finding molecules of therapeutic interest, studies should be 
undertaken to determine the activity profile of the compounds on a large panel of cell lines 
form cancerous and normal origins, and the possible mechanisms of resistance, in addition to 
in vivo studies performed in animal models. Second, on the “chemical side”, we will keep 
updating and expanding the database of Vietnam natural compounds not only from plant and 
marine resources but also from micro-organisms. One may expect or hope that this will be a 
mean to increase the chances to discover a “yet hidden” natural compound of highest 
therapeutic interest, not only in cancer but also in any deadly disease affecting our modern 
societies, whatever their level of development. 
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ABSTRACT
Human hepatocellular carcinoma (HCC) is the most common type of liver cancer,
the second most common cause of death from cancer worldwide. A very poor
prognosis and a lack of effective treatments make liver cancer a major public
health problem, notably in less developed regions, particularly in eastern Asia.
This fully justifies the search of new molecules and therapeutic strategies against
HCC. Ent-kaurane diterpenoids are natural compounds displaying a broad spec-
trum of potential therapeutic effects including anticancer activity. In this study,
we analyzed the pharmacological properties of a family of ent-kaurane diter-
penoids from Croton tonkinensis Gagnep in human HepG2 and Hep3b cell lines,
used as cellular reference models for in vitro evaluation of new molecules active
on HCC. A structure-related cytotoxicity was observed against both HCC cell
lines, enlighting the role of the 16-en-15-one skeleton of ent-kaurane diter-
penoids. Cytotoxicity was closely correlated to apoptosis, evidenced by concentra-
tion-dependent subG1 cell accumulation, and increased annexin V expression. In
addition, subtoxic concentration of ent-kaurane diterpenoid dramatically enhanced
the sensitivity of HCC cells to doxorubicin. All together, our data bring strong
support to the potential interest of ent-kaurane diterpenoids, alone or in combina-
tion with a cytotoxic agent, in cancer and more precisely against HCC.
INTRODUCT ION
Hepatocellular carcinoma (HCC) is the most common
type (>80%) of liver cancer which has become the sec-
ond most common cause of death from cancer world-
wide, with estimated 746 000 deaths and 782 000 new
cases in 2012, according to the most recent GLOBOCAN
data from the International Agency for Research on
Cancer (http://www.globocan.iarc.fr/) [1]. More than
80% of these deaths and new cases occur in the less
developed regions, particularly in eastern Asia, making
liver cancer a major public health problem in these
countries. The very poor prognosis for liver cancer (over-
all ratio mortality/incidence: 0.95) together with the
lack of effective treatments makes the search of new
molecules and/or new therapeutic strategies a challeng-
ing goal.
As a part of our ongoing program aimed at identify-
ing Vietnamese natural compounds endowed with
antiproliferative properties against HCC, we focused our
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efforts on ent-kaurane diterpenoids from Croton tonki-
nensis Gagnep. Ent-kaurane diterpenoids isolated from
various species display a wide variety of pharmacologi-
cal effects such as anti-inflammatory, antibacterial, or
antitumor activity, this latter one representing an
attractive basis for the recent development of potential
anticancer therapeutic agents [2,3]. The genus Croton
L. (Euphorbiaceae) consists of about 800 species
mainly distributed in tropical regions, among which 31
are cultivated or grow wild in northern Vietnam. Cro-
ton tonkinensis Gagnep, commonly named in Viet-
namese as ‘Kho sam Bac Bo’, is a tropical shrub native
to northern Vietnam [4]. It has been used commonly
in traditional prescription to treat leprosy, psoriasis,
malaria, and genital organ prolapse [4,5]. Ent-kaurane-
type diterpenoids were isolated from the leaves of Cro-
ton tonkinensis Gagnep, and their structure determined
from phytochemical investigations [6–8]. For some of
them, the cytotoxic properties have been tested against
breast MCF-7, lung A549 [6], liver SK-HEP1 [9],
intestinal CaCo-2, and colon LS180 [10] cancer cell
lines.
Regarding liver cancer, the well-characterized
human cell lines HepG2 and Hep3b represent cellular
reference models for in vitro pharmacological studies,
proven to be well adapted for the study of new mole-
cules active on HCC [11]. Of the various ent-kaurane
diterpenoids from Croton tonkinensis described so far in
the literature, only one has been tested against one
HCC cell line (SK-HEP1) [9], and to our knowledge,
none has been studied against the two HCC cell line
pharmacological models. In this study, we selected a
family of seven ent-kaurane diterpenoid compounds
and tested their cytotoxic and apoptotic effects on both
human liver HepG2 and Hep3b cell lines. Because it
has been shown that natural products can enhance
the sensitivity of human HCC cells to the cytotoxic
effect of doxorubicin, an anthracycline used in HCC
treatment [12,13], we further explored the ability of
the ent-kaurane diterpenoids to enhance doxorubicin
cytotoxicity in the HepG2 and Hep3b model cell lines.
MATER IALS AND METHODS
Plant material and chemical properties
The ent-kaurane diterpenoids were previously isolated
from the leaves of the plant Croton tonkinensis. The
purification and structure identification of the com-
pounds were performed at the Institute of Natural
Products Chemistry—Vietnam Academy of Science and
Technology. The purity of the compounds was deter-
mined as ≥97% by HPLC. The list of the compounds 1
to 7 is presented in Table I and their structure shown
in Figure 1. Doxorubicin (doxorubicin hydrochloride)
was purchased from Sigma-Aldrich.
Cell lines and cell culture
Human liver cancer cell lines HepG2 (ATCC HB8065)
and Hep3b (ATCC HB8064) were purchased from Amer-
ican Type Culture Collection (ATCC; Manassas, VA,
USA) and cultured in Dulbecco’s modified Eagle’s med-
ium (DMEM) (Hyclone, USA) supplemented with 10%
fetal bovine serum (Hyclone), 100 U/mL penicillin, and
100 lg/mL streptomycin at 37 °C in a humidified atmo-
sphere with 5% CO2 and 95% humidity.
Cell viability assay
Once reached about 80% confluency, cells were
detached using 0.05% trypsin/EDTA and counted. Cells
were then resuspended and added onto 96-well plate
and allowed to attach for 24 h. Each tumor cell line
was exposed to the ent-kaurane diterpenoid compounds
1 to 7 at various concentrations in triplicate for 24 or
48 h. Doxorubicin was used as positive control. Cell
viability was assessed following the MTT assay protocol
[14].
SubG1 analysis by flow cytometry
To investigate the pro-apoptotic effect of the ent-kaur-
ane diterpenoids, HepG2 and Hep3b cell types were
treated with compound 5 at various concentrations
(0, 2, 4, 8, 16 lM) for 48 h at 37 °C. Cells were disso-
ciated with 0.05% trypsin/EDTA, harvested, washed
with the buffer solution containing sodium citrate, and
then incubated with the DNA reagents according to
the BD CycleTestTM Plus DNA Reagent kit protocol
(BD Biosciences, Becton Dickinson France SA, Le Pont
de Claix, France). The cellular DNA was stained with
propidium iodide at a final concentration of at least
125 lg/mL and analyzed. The flow cytometric analysis
was performed using the LSRII flow cytometer (BD Bio-
sciences).
Apoptosis analysis by flow cytometry
The apoptosis process was evaluated using the BD
PharmigenTM Annexin V: FITC Apoptosis Detection
Kit (BD Biosciences). Cells were seeded at a density of
4 9 105/mL into 6-well plates for Hep3b cell type and
6 9 105/mL into 24-well plates for HepG2 and then
treated with varying concentrations (0, 2, 4, 8, 16 lM)
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of compound 5. After incubation at 37 °C for 48 h,
cells were dissociated with Gibco Cell Dissociation Buf-
fer, enzyme free, PBS (Life Technologies), harvested,
washed in cold PBS, and then pelleted. According to
the manufacturer’s instructions, cells were stained in
the dark for 15 min at room temperature and analyzed
by flow cytometry within 1 hr of ending the staining
procedure. Apoptosis was analyzed using the LSRII
flow cytometer (BD Biosciences).
Time-course analysis of cell sensitization to
doxorubicin cytotoxicity
HepG2 and Hep3b cells were incubated during 6, 12,
24, or 48 h in the absence or presence of doxorubicin
(at 20 lM or at increasing concentrations) alone or in
combination with compound 5 at a subtoxic concen-
tration (1 lM). As control, cytotoxicity of compound 5
alone at 1 lM was evaluated. Cell viability was mea-
sured using a MTT assay.
Statistical analysis
All experiments were performed at least three times.
Values were expressed as mean  SD. The half maxi-
mal inhibitory concentrations (IC50) were determined
using the GraphPad Prism software (GraphPad Soft-
ware, Inc. San Diego, CA, USA). Differences were ana-
lyzed using the Student’s t-test. Differences with
P < 0.05 (*) or P < 0.001 (***) were considered statis-
tically significant.
RESULTS
Cytotoxic effects of ent-kaurane diterpenoid
compounds 1 to 7 on human HCC HepG2 and
Hep3b cell lines
As shown in Table II, all the seven compounds elicited
a cytotoxic activity against both HepG2 and Hep3b
cell lines, mainly without marked difference between
the two cell lines, for a given compound. The activity
remained similar or weakly enhanced from 24 to
48 h of incubation, with most of the IC50 values
ranging from 3 to 10 lM. Cytotoxicity varied, depend-
ing on the compound. Compound 5 was the most
active, with IC50 values around 3 lM, followed by
compound 6. Compound 1 and compound 4 and,
to a lesser extend, compound 2 displayed similar
Table I Name (IUPAC) and chemical
entities for R1 to R5 of the ent-
kaurane-type diterpenoid compounds 1
to 7.
Name (IUPAC) R1 R2 R3 R4 R5
1 ent-18-acetoxy-7b-hydroxykaur-16-en-15-one (C22H32O4) H OAc OH H =CH2
2 ent-1a-acetoxy-7b,14a-dihydroxykaur-16-en-15-one (C22H32O5) OAc H OH OH =CH2
3 ent-16(S)-18-acetoxy-7b-hydroxykaur-15-one (C22H34O4) H OAc H OH -CH3
4 ent-7b,14a-dihydroxykaur-16-en-15-one (C20H30O3) H H OH OH =CH2
5 ent-18a-acetoxy-7a,14b-dihydroxykaur-16-en-15-one (C22H32O5) H OAc OH OH =CH2
6 ent-1a,14a-diacetoxy-7b-hydroxykaur-16-en-15-one (C24H34O6) OAc H OH OAc =CH2
7 ent-1a,7b-diacetoxy-14a-hydroxykaur-16-en-15-one (C24H34O6) OAc H OAc OH =CH2
R5
O
R4
R1
R2-H2C
R3
CH2
O
R4
R1
R2-H2C
R3
H
C C
O
R4
R1
R2-H2C
R3
H
H
H
(a)
(b) (c)
R1 R2 R3 R4 R5
1 H OAc OH H =CH2
2 OAc H OH OH =CH2
3 H OAc H OH −CH3
4 H H OH OH =CH2
5 H OAc OH OH =CH2
6 OAc H OH OAc =CH2
7 OAc H OAc OH =CH2
Figure 1 Chemical structure of ent-
kaurane-type diterpenoid compounds 1
to 7. (a)The structure common to all the
seven compound is represented. For
each compound (1 to 7), the chemical
entities of group R1 to R5 are specified.
(b) Structure with arrows illustrating
the conjugation effect for compounds 1,
2, 4, 5, 6, and 7. (c) Structure with
arrows illustrating the hyperconjugation
effect for compound 3.
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activities with IC50 values below or close to 10 lM.
Compound 7 exhibited a lower cytotoxicity with IC50
values above 10 lM. Finally, compound 3 clearly dis-
played the weakest activity, with IC50 values in the
100 lM range.
Induction of subG1 phase by ent-kaurane
diterpenoid compound 5 on human HCC HepG2
and Hep3b cell lines
To further explore the cellular mechanisms underlying
the observed cytotoxic effects, compound 5, for which
the cytotoxic properties have not been tested in the lit-
erature, was used as the representative molecule of the
series of compounds.
Compound 5 was tested in a range of concentrations
framing its IC50 values. Results are shown in Figure 2.
Panel A illustrates the cell population observed in the
absence or presence of increasing concentrations of
compound 5 in representative experiments performed
on HepG2 (upper panels) and Hep3b (lower panels) cell
lines. Panel B shows that in the absence of compound
5, the subpopulation of both HepG2 and Hep3b cell
lines in the subG1 phase was low, around 10%
(11.2  2.1 for HepG2 and 10.6  6.9 for Hep3b). In
the presence of compound 5, the % of cells in the
subG1 phase increased in a concentration-dependent
manner, from around 30% (35.0  13.3 for HepG2
and 27.5  3.3 for Hep3b) at 2 lM of compound 5 to
around 80% (80.3  15.0 for HepG2 and
73.7  11.1 for Hep3b) at 16 lM of compound 5. At
the concentration of 4 lM, about half of the cell popu-
lation was in the subG1 phase (56.0  12.3 for HepG2
and 40.4  9.7 for Hep3b).
Apoptotic properties of ent-kaurane diterpenoid
compound 5 on human HCC HepG2 and Hep3b
cell lines
Results are presented in Figure 3. Panel A illustrates the
observed cell population in the absence or presence of
increasing concentrations of compound 5 in a represen-
tative experiment performed on HepG2 cell line. A simi-
lar pattern was obtained with the Hep3b cell line (not
shown). As shown in panels B (HepG2) and C (Hep3b), a
high proportion (%) of cells was viable and nonapoptotic
(73.8  2.1 for HepG2 and 79.4  8.3 for Hep3b) in
the absence of compound 5. When treated with com-
pound 5, the % of viable cells declined in a concentra-
tion-dependent manner. The population of viable cells at
4 lM was slightly below 50% (37.9  4.1 for HepG2
and 43.5  17.7 for Hep3b). At the highest concentra-
tion tested, viability of HepG2 cells was dramatically
affected (4.1  3.5) whereas that of Hep3b cells
remained rather stable (19.3  4.1). In parallel, there
was an increase in early apoptotic cell populations
which reached a plateau around 40% for both cell lines
at the highest concentration of compound 5
(34.7  7.2 for HepG2 and 38.9  14.7 for Hep3b).
The number of cells in the double positive cell popula-
tion (which contains late apoptotic and/or necrotic cells)
also increased, in a continuous manner for HepG2
(60.6  3.5) but with a stabilization around 40% for
Hep3b (41.4  11.9) at 16 lM of compound 5.
Effect of ent-kaurane diterpenoid compound 5 on
doxorubicin cytotoxicity in human HCC HepG2
and Hep3b cell lines
Results are shown in Figure 4 and Table III. Cytotoxicity
of doxorubicin alone increased regularly with IC50 val-
ues ranging from 109.3  7.7 lM to 26.5  1.8 lM for
HepG2 and from 86.9  7.3 lM to 25.1  2.1 lM for
Hep3b between 6 and 48 h of incubation (Table III). As
shown in Figure 4, from 12 to 48 h, compound 5 dra-
matically enhanced the cytotoxicity of 20 lM doxoru-
bicin, cell viability decreasing to less than 5% at 48 h
(compared to 60% for doxorubicin alone). Accordingly,
a significant—8- to 11-fold—decrease was measured for
the IC50 values (Table III). Conversely however at 6 h of
incubation, compound 5 had only a weak to moderate
effect on the IC50 values (IC50 ratio <2, Table III) and did
not enhance the cytotoxic effect of 20 lM doxorubicin
(Figure 4) in both cell lines.
Table II Cytotoxic activity (IC50, lM) of ent-kaurane diterpenoids
(compounds 1 to 7) on human HCC HepG2 and Hep3b cell lines
after 24 and 48 h of incubation. Doxorubicin (Dox) was used as
positive control. Results are expressed as the mean  SD values
from three independent experiments.
Compound
IC50 (lM)
24 h 48 h
HepG2 Hep3b HepG2 Hep3b
1 8.3  1.5 8.0  0.6 3.6  1.5 8.6  0.4
2 10.2  3.3 9.9  1.2 9.6  3.1 8.5  0.7
3 98.6  25.4 116.2  41.6 85.2  32.5 69.6  13.9
4 8.4  1.8 7.8  2.3 3.9  0.3 6.1  0.5
5 3.1  0.5 9.0  0.4 3.5  0.8 3.7  0.1
6 5.7  1.2 9.5  0.5 5.0  1.2 6.1  0.5
7 12.1  3.9 16.1  5.8 13.7  1.3 9.7  0.1
Dox 50.8  3.3 49.3  17.3 26.5  1.8 25.1  2.1
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DISCUSS ION
Ent-kaurane diterpenoid compounds 1 to 7
display cytotoxicity in human HCC HepG2 and
Hep3b cell lines
All the seven compounds elicited a concentration-depen-
dent cytotoxic activity against both HepG2 and Hep3b
cell lines without marked difference between the two cell
lines. The fact that no significant difference was observed
in the cytotoxic effect against HepG2 and Hep3b despite
the distinct pharmacological properties of the two cell
lines [11], suggested a cell line-independent mechanism
of action of the compounds. Indeed, it is accepted that
the cytotoxicity of ent-kaurane diterpenoids results from
the formation of reactive oxygen species (ROS) through
Michael reaction with regulatory thiol-containing
enzymes or coenzymes [15–17], likely to be shared by
the two HepG2 and Hep3b cell lines and others.
Cytotoxicity of compound 1 on HepG2 and Hep3b
cell lines was in the same range as that measured on
the SK-HEP1 cell line for the identical ent-kaurane
diterpenoid named CrT1 [9]. Activity of compounds 1,
2, and 4 against HCC HepG2 and Hep3b cell lines was
comparable to the activity of identical molecules
described against other tumor cell lines such as A549
(lung), MCF-7 (breast), or KB (epidermoid carcinoma)
[6]. Compounds 1, 2, 6, and 7 were also found active
in the brine shrimp lethality assay [18]. Interestingly,
all the compounds except compound 3 share the O=C-
CH=CH2 system, described to be responsible of the
cytotoxicity of sesquiterpene antitumor agents [19,20],
and possess the 16-en-15-one basic skeleton shown to
play an important role in the cytotoxic activity of ent-
kaurane diterpenoids [6,10]. Conversely, the absence of
an hydroxyl group at C7 position may contribute to a
decreased activity [6]. Consistent with this observation,
compound 7, bearing the 16-en-15-one structure but
lacking the hydroxyl group at the C7 position, exhib-
ited, to a lesser extend, a decreased activity with IC50
values above 10 lM. Further, our observation corre-
lates with the weak cytotoxic activity measured for
compound 7 in the brine shrimp lethality assay [18].
Compound 3 which lacks both the 16-en-15-one basic
skeleton and an hydroxyl group at C7 position dis-
played the weakest activity, with IC50 values in the
100 lM range, that is, 10 to 30 times higher than
those of compound 5. Interestingly, it must be noticed
that the R5 methyl group, which results in a well-
(a)
(b)
Figure 2 Pro-apoptotic effect of ent-
kaurane-type diterpenoid compound 5
on human HCC HepG2 and Hep3b cell
lines. (a) Hep G2 (upper panels) and
Hep3b (lower panels) cells were
incubated with no (control) or
increasing concentrations (2–16 lM) of
compound 5 for 48 h followed by
staining with propidium iodide (PI).
DNA content was analyzed by flow
cytometry. The number of cells (cell
count) is represented as a function of
DNA content (PI). The % of cells in
subG1 is indicated. Data presented are
from one representative experiment. (b)
Histograms showing the % of cells in
subG1 phase as a function of increasing
concentrations of compound 5.
Columns and bars are the mean and SD
from 3 independent experiments.
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known hyperconjugation effect (Figure 1), is only pre-
sent in compound 3. Hyperconjugation leads to a more
stable structure and, consequently, to a less reactive
functionality, which may affect the biological properties
of ent-kaurane diterpenoids. In accord with our obser-
vation, an ent-kaurane diterpenoid identical to com-
pound 3 showed no cytotoxicity in the brine shrimp
lethality assay [18] and was inactive in other biological
assays such as inhibition of Silent information regula-
tor two ortholog (SIRT1) [21] or antistaphylococcal
activity [22]. Finally, compound 5, for which the cyto-
toxic properties have not been explored before, exhib-
ited the more efficient activity and was therefore
defined as the representative molecule of the series for
further studies.
Ent-kaurane diterpenoid compound 5 displayed
pro-apoptotic properties in human HCC HepG2
and Hep3b cell lines
Cytometry analysis of the cell population in the
subG1 phase is commonly used to evaluate the pro-
apoptotic properties of antitumor molecules. In the
presence of compound 5, the number of cells in the
subG1 phase increased in a concentration-dependent
manner. This observation evidenced the pro-apopto-
tic effect of compound 5. Although the difference
was not statistically different, the % of subG1 popu-
lation in the presence of compound 5 was repeat-
edly and consistently higher for HepG2 than Hep3b
at a given concentration of compound 5, suggesting
a different sensitivity between the two cell lines. At
(a)
(b)
Figure 3 Induction of apoptosis of human HCC HepG2 and Hep3b cell lines by ent-kaurane-type diterpenoid compound 5. HepG2 and
Hep3b cells were incubated with no (control) or increasing concentrations (2–16 lM) of compound 5 for 48 h followed by staining with
Annexin V FITC and propidium iodide (PI). DNA content and Annexin V expression were analyzed by flow cytometry. (a) Data presented
are from one representative experiment performed on HepG2 cell line. In the upper left panel, the light scattered properties of untreated
cells (FSC-A, SSC-A) are shown. In each other panel, viable, early apoptotic, and late apoptotic cells are gated in lower left, lower right,
and upper right quarters, respectively (debris are shown in upper left quarter). Comparable pattern was observed with Hep3b cell line
(not shown). (b and c) Percentage (%) of viable, early apoptotic, and late apoptotic (black, white, and gray columns, respectively) HepG2
(b) and Hep3b (c) cells as a function of increasing concentrations of compound 5. Columns and bars are the mean and SD from 3
independent experiments.
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a concentration of 4 lM, close to the IC50 values
determined in the cytotoxicity assay at 48 h (see
Table II), about half of the cell population was in
the subG1 phase for HepG2 and for Hep3b. This is
in favor of a correlation between the cytotoxic and
pro-apoptotic properties of compound 5. Interest-
ingly, the % of subG1 population of HepG2 and
Hep3b cell lines induced by compound 5 in our
study were quite comparable to those obtained with
CrT1 (identical to compound 1) on the SK-HEP1 cell
line [9]. These findings, observed on three different
HCC cell lines, suggested that ent-kaurane diter-
penoids might share common or closely related pro-
apoptotic mechanisms of action leading to apoptosis
in human HCC cell lines.
Concentration-dependent induction of apoptosis
by ent-kaurane diterpenoid compound 5 in
human HCC HepG2 and Hep3b cell lines
Concomitant analysis of annexin V and propidium
iodide by flow cytometry allowed the identification of
early and late apoptotic stages and therefore brought a
more detailed insight on ent-kaurane diterpenoid-
induced apoptosis. The number of viable cells treated
with compound 5 declined in a concentration-depen-
dent manner. In good agreement with the IC50 values
and the observations made in subG1 experiments, the
population of viable cells at 4 lM was slightly below
50%. This further supported the link, suggested above,
between the cytotoxic and apoptotic properties of com-
pound 5. At the highest concentration tested, the
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Figure 4 Sensitization of human HCC HepG2 and Hep3b cell lines to doxorubicin cytotoxicity by ent-kaurane-type diterpenoid compound
5. Cell viability was analyzed as a function of time and measured using a MTT assay. HepG2 (left panel) and Hep3b (right panel) cells
were incubated during 6, 12, 24, or 48 h with 20 lM doxorubicin alone (full circle) or in combination (full square) to compound 5 at a
subtoxic concentration (1 lM). As control, compound 5 alone at 1 lM (open triangle) exhibited no significant cytotoxicity. Values shown
are the mean  SD from three independent experiments. For a given time, P values <0.05 (*) or <0.001 (***) indicated statistically
significant differences between measures performed with doxorubicin alone and in combination with compound 5.
Table III Cytotoxic activity (IC50, lM) of doxorubicin (Dox) in the absence or in the presence of ent-kaurane diterpenoid compound 5 (cpd
5) on human HCC HepG2 and Hep3b cell lines after 6, 12, 24, and 48 h of incubation. Results are expressed as the mean  SD values
from three independent experiments. For a given time, the ratio of the IC50 values of doxorubicin in the absence/in the presence of
compound 5 is shown in parentheses.
Incubation time (h)
IC50 (lM)
HepG2 Hep3b
Dox Dox + cpd 5 Dox Dox + cpd 5
6 109.3  7.7 79.4  6.0 (1.4) 86.9  7.3 64.5  3.8 (1.3)
12 66.6  13.4 9.2  0.9 (7.2) 56.2  3.0 6.2  0.5 (9.1)
24 50.8  3.3 4.8  0.6 (10.6) 49.3  17.3 5.1  0.3 (9.7)
48 26.5  1.8 3.2  0.6 (8.3) 25.1  2.1 2.3  0.3 (10.9)
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important drop in cell viability of HepG2 cells
contrasted with the rather stability of Hep3b cells, sug-
gesting, as noted before, a different sensitivity of the
two cell lines. In HepG2 cells, the high number of late
apoptotic cells correlated with the low number of viable
cells. In striking contrast with our observation, late
apoptosis was barely detectable in HepG2 cells treated
with longikaurin A, a natural ent-kaurane [23].
Two additional and complementary observations sus-
tained the evidence of apoptosis in both HepG2 and
Hep3b cell lines. First, under light microscope, we
observed rounded and shrinked cells upon treatment of
both cell lines. Second, in correlation with these mor-
phological changes, treated cells showed altered flow
cytometry light scatter properties, with a decrease in
forward scatter (FSC-A, x-axis) and an increase in side
scatter (SSC-A, y-axis), which resulted from cell shrink-
ing and apoptotic vesicles formation, respectively (not
shown). The cellular components involved in apoptosis
of HepG2 and Hep3b cells lines induced by compound
5 remain to be identified. Along this line, two different,
but not exclusive, apoptotic cellular pathways triggered
by ent-kaurane diterpenoids in two different HCC cells
have been reported recently: the regulation of AMP-
activated protein kinase by CrT1, isolated from Croton
tonkinensis in SK-Hep1 cells [9], and the activation of
ROS/JNK/c-Jun pathway by longikaurin A, isolated
from Isodon ternifolius, in SMMC-7721 cells [23].
Subtoxic concentration of ent-kaurane
diterpenoid compound 5 strongly enhances the
cytotoxicity of doxorubicin in human HCC HepG2
and Hep3b cell lines
Doxorubicin is one of the most commonly used
chemotherapeutic agent against various cancers
including HCC [12,13]. However, as a single agent,
efficacy of doxorubicin against HCC remains limited,
mainly due to chemoresistance and severe side effects
[24]. Combined therapy has emerged as a strategy for
improving the therapeutic effects of doxorubicin in
HCC [25,26]. In this field, few natural molecules have
been successfully used to enhance the cytotoxic effect
of doxorubicin in ovarian [27] or liver [28–30] cancer
cells. In our study, a low, subtoxic concentration of
compound 5 efficiently sensitized both HepG2 and
Hep3b cell lines to doxorubicin cytotoxicity in a time-
dependent manner. However, this effect was not
observed within the first 6 h. This 6 h-delay ruled out
the hypothesis of an immediate, nonspecific action of
compound 5, such as disruption of the cellular
membrane integrity, which would allow doxorubicin to
better penetrate the cell. It indicated that the sensitiza-
tion effect of compound 5 necessitated triggering of
intracellular pathways, which remain to be character-
ized. Enhanced ROS production has been associated to
the synergistic effects between doxorubicin and with-
aferin A in ovarian cancer [27] or selenocysteine in
HCC [29]. Interestingly, as discussed above, ent-kaur-
ane diterpenoid-induced formation of ROS also medi-
ates cytotoxicity [17] and apoptosis [10]. The fact that
ROS generation is also one of the mechanisms of action
involved in doxorubicin antitumor activity [31,32]
may be a possible explanation of the observed additive
effects between compound 5 and doxorubicin.
All together, these data suggest that ent-kaurane
diterpenoid-induced ROS formation may play a dual
role in cancer cells: sensitization at low subtoxic con-
centrations on the one hand and apoptosis-mediated
cytotoxicity at higher concentrations on the other.
As previously proposed for other natural products
[27–30], interaction of ent-kaurane diterpenoids with
doxorubicin may be viewed as a possible way to
enhance the antitumor therapeutic effects of doxoru-
bicin. Conversely, ROS accumulation is involved in the
cardiotoxic side effects of doxorubicin [32,33] and
cumulative ROS generation could then result in an
unwished potentiation of cardiotoxicity.
CONCLUS ION
Our study not only showed that ent-kaurane diter-
penoids displayed a structure-related, concentration-
dependent, apoptosis-induced cytotoxicity against two
human HCC model cell lines but also revealed that
they were active at subtoxic concentration, by sensitiz-
ing HCC cells to the anticancer agent doxorubicin.
These data bring strong support to the potential inter-
est of ent-kaurane diterpenoids in the cancer field and
more precisely against HCC. Even though virtually no
acute toxicity has been observed in vivo [34], the side
effects of ent-kaurane diterpenoids remain poorly docu-
mented to date and their careful evaluation should be
undertaken, in a perspective of future clinical applica-
bility and development [2]. In parallel, one may expect
that the intrinsic low aqueous solubility and weak
bioavailability of these natural products [35] could be
successfully overcome through, for example, ent-kaur-
ane-based design of synthetic molecules [36].
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Abstract : 
Human hepatocellular carcinoma (HCC) is the most common type of liver cancer, the 
second most common cause of death from cancer worldwide. A very poor prognosis and a 
lack of effective treatments make liver cancer a major public health problem, notably in less 
developed regions, particularly in Eastern Asia. This fully justifies the search of new 
molecules and therapeutic strategies against HCC. The present work focused on finding 
bioactive compounds from Vietnamese plants against HCC. The first approach used 
classical screening of 33 natural compounds which resulted in the identification of 7 ent-
kaurane diterpenoids isolated from Croton kongensis Gagnep. as potential agents. The 
second approach aimed at identifying molecules that could abrogate the interaction between 
Mortalin and p53 by in silico screening of a database of 354 natural compounds, which 
allowed the identification of Solasonine as a potent inhibitor of p53 – mortalin interactions. 
 
 
  
AUTEUR : Minh Quan PHAM 
TITRE : Bio-pharmacological screening on liver-protective and anti-hepatocarcinoma 
activities of Vietnam natural products 
DIRECTEUR DE THESE : Pr. Jean Edouard GAIRIN  
LIEU ET DATE DE SOUTENANCE : Université Paul Sabatier, Toulouse, le 30 Mai 
2016 
 
RESUME 
Le carcinome hépatocellulaire (HCC) est le cancer du foie le plus répandu et représente 
la seconde cause de décès par cancer dans le monde. Un mauvais pronostic et l’absence 
de traitement efficace en font un problème majeur de santé publique dans les pays en 
voie de développement, notamment en Asie du Sud-Est, justifiant pleinement la 
recherche de molécules ou d’approches thérapeutiques nouvelles contre l’HCC. Ce 
travail porte sur la recherche de molécules isolées de plantes vietnamiennes actives 
contre l’HCC. La première approche a consisté en un criblage pharmacologique de 33 
substances naturelles qui a conduit à l’identification de 7 ent-kaurane diterpénoïdes isolés 
de Croton kongensis Gagnep. présentant des propriétés antiprolifératives originales. La 
seconde approche, par criblage in silico d’une banque de 354 substances naturelles, a 
permis d’identifier la solasonine comme inhibiteur de l’interaction mortalin – p53 
induisant l’apoptose dans la lignée cellulaire humaine HepG2. 
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